

ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2015

Cancer in Slovenia



Rak
v Sloveniji

2015

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2015 / Cancer in Slovenia 2015

Uredniški odbor / Editorial Board

Vesna Zadnik, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Urška Ivanuš,
Katja Jarm, Vera Pompe-Kirn, Primož Strojjan,
Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Tina Žagar in Katarina Lokar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo, Ljubljana

Tisk / Printing

Grafika Gracer d.o.o., Celje

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Slovenia

Naklada / Published in

600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2015. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2018.

Cancer in Slovenia 2015. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2018.

Osebnje Registra raka Republike Slovenije / Staff of the Cancer Registry of Slovenia

Vesna Zadnik, vodja / head
Barbara Babuder, Maruška Ferjančič, Andrej Kirn, Andrej Krašovec, Katarina Lokar,
Darja Strle, Fani Škrlec, Polona Škulj, Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:

<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

<http://www.slora.si/>
<http://www.slora.si/en/>

Uvod	7
Viri podatkov in metode registracije	9
Viri podatkov	9
Priprava podatkov za računalniško obdelavo	10
Kakovost podatkov RRRS in popolnost registracije	11
Statistične metode	12
Incidenca in umrljivost	12
Grobe in starostno specifične stopnje	12
Starostno standardizirane stopnje	12
Kumulativne stopnje in kumulativno tveganje	13
Prevalenca	13
Preživetje	14
Prebivalstvo Slovenije	15
Rak v Sloveniji 2015	16
Zahvala	20
Introduction	21
Data sources and methods of registration	23
Data sources	23
Preparation of data for computer processing	24
Data quality and completeness of registration	25
Statistical methods	27
Incidence and mortality	27
Crude and age specific rates	27
Age standardised rates	27
Cumulative incidence rate and cumulative risk	28
Prevalence	28
Survival	28
Population of Slovenia	30
Cancer in Slovenia 2015	31
Acknowledgment	35
Reference / References	36

Slike / Figures

Slika 1:	Breme raka, Slovenija 2015.	38
Figure 1:	Cancer burden, Slovenia 2015.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2015.	38
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2015.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2015.	39
Figure 3:	The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2015.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2015.	40
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2015.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2015.	41
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2015.	
Slika 6:	Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2006–2010 in 2011–2015 po spolu in pri obeh spolih skupaj.	42
Figure 6:	Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2006–2010 and 2011–2015 by sex and for both sexes together.	
Slika 7a:	Rak dojke - starostno standardizirana pet-letna čista preživetja pri odraslih ženskah (15–99 let) po evropskih državah in obdobjih diagnoze 2000–2014: raziskava Concord-3.	45
Figure 7a:	Breast cancer – age-standardised five-year net survival in women (15–99 years), by European countries and calendar period of diagnosis 2000–2014: Concord-3 study.	
Slika 7b:	Časovni trend starostno specifičnih incidenčnih stopenj raka dojk pri ženskah s povprečno letno spremembo za zadnjih 10 let, Slovenija 1961–2015.	46
Figure 7b:	Time trend of age specific incidence rate of breast cancer (women) with average annual change in last 10 years, Slovenia 1961–2015.	
Slika 7c:	Časovni trend pet-letnega čistega preživetja bolnic z rakom dojk po starostnih skupinah, Slovenija 1985–2015.	46
Figure 7c:	Time trend of five-year net survival of breast cancer (women) by age group, Slovenia 1985–2015.	
Slika 7d:	Bolnice z rakom dojke stare med 50 in 69 let glede na udeležbo v presejalnem programu DORA po lokaciji, histološki vrsti, stadiju in načinu prvega zdravljenja, Slovenija 2011–2015.	47
Figure 7d:	Breast cancer (women aged 50–69 years) according to attendance in organised screening programme DORA by site, histological type, stage and first curative treatment, Slovenia 2011–2015.	
Slika 7e:	Pet-letno čisto preživetje bolnic z rakom dojk starih 50–69 let glede na udeležbo v presejalnem programu DORA, Slovenija 2011–2015.	48
Figure 7e:	Five-year net survival of breast cancer (women aged 50–69 years) according to attendance in organised screening DORA, Slovenia 2011–2015.	
Slika 7f:	Čas do prvega zdravljenja (operacija, sistemska terapija ali obsevanje) pri bolnicah z rakom dojk po statističnih regijah, Slovenija 2013.	48
Figure 7f:	Time to first treatment (surgery, systematic treatment or radiotherapy) in breast cancer patients by statistical regions, Slovenia 2013.	
Slika 7g:	Definicije in stopnje doseganja izbranih kazalnikov kakovosti oskrbe bolnic z rakom dojk, Slovenija 2013.	49
Figure 7g:	Definitions and adherence rates of selected breast cancer care quality indicators, Slovenia 2013.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2006–2015 in 2018.	50
Table 1:	Observed and estimated cancer incidence, Slovenia 2006–2015 and 2018.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2015.	51
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2015.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2015.	52
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2015.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2015.	56
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2015.	
Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2015.	60
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2015.	
Tabela 6a:	Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2015.	66
Table 6a:	Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2015.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2015.	67
Table 6b:	Age standardised incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2015.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2015.	68
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2015.	
Tabela 8:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2015.	77
Table 8:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2015.	
Tabela 9:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2015.	80
Table 9:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2015.	
Tabela 10:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2015.	81
Table 10:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2015.	
Tabela 11a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.	83
Table 11a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 11b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	84
Table 11b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by surgery during their first treatment by primary site and treatment institution.	

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po lokaciji raka in bolnici zdravljenja.	85
Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by systemic therapy during their first treatment by primary site and treatment institution.	
Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2015.	86
Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2015.	
Tabela 13: Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2015.	87
Table 13: Cancer mortality by site, by sex and by age, Slovenia 2015.	
Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2011–2015 po spolu.	90
Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2011–2015 by sex.	
Izbor publikacij / Selected publications	91

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka; do leta 2018 jo je vodila dr. Maja Primic Žakelj. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 do 3 leta. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2018); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977 in 2007–2014), v vmesnem obdobju (1978–2006) pod imenom *Incidenca raka v Sloveniji*, in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so bile objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih* (*Cancer Incidence in Five Continents*), ki jo izdaja Mednarodna

agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *CONCORD-3*, *RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2015 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.


Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje. Dopolnilni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakah, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojke in SVIT za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. S prijavnici zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Veliko časa porabimo za poizvedbe o bolnikih, za katere na prijavnicih niso zapisani popolni ali ustrezni podatki ter za tiste o katerih dobimo prvo informacijo šele iz enega od dopolnilnih virov.

Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Podrobne analize prostorske razporeditve raka nam omogoča točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS. V Tabeli 6 tako prikazujemo breme raka na ravni 12 statističnih regij kot so bile v slovenskem prostoru v veljavi leta 2015.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih

v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Ginekološke tumorje tako opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu pa beležimo tudi velikost po Clarku in Breslowu. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2018 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo Joinpoint Regression Program (Verzija 4.1.1 – Avgust 2014), ki je narejen na podlagi metodologije, ki so jo razvili Kim s sodelavci.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so v istem obdobju izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 človek-let. *Starostno specifična stopnja* (incidenčna oz. umrljivostna stopnja) se izračuna na enak način, vendar za posamezno starostno skupino.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, ki bi jo opazili, če bi bila starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji prikazujemo še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je

vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zbolí za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojke pri ženskah 7,8/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojke, ki je v tem primeru 7,5-odstotno. To pomeni, da bo 7,5 % deklic (ali približno ena od 13), rojenih leta 2015, do 74. leta starosti verjetno zbolelo za rakom dojke.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih diagnoz.

Preživetje

Pri skupinah bolnikov preživetje predstavlja delež bolnikov, ki so po izbranem časovnem obdobju od postavitve diagnoze še živi. Možnosti in metod za izračun preživetja je več. Osnovna in hkrati najpreprostejša mera preživetja je tako imenovano opazovano preživetje, kjer v izračun vključimo vse smrti, tudi tiste, ki jih ni povzročilo rakavo obolenje. Za oceno preživetij bolnikov z rakom, v kateri upoštevamo kot vzrok smrti le proučevanega raka, v populacijskih izračunih uporabljamo metode relativnega in čistega preživetja. Uradni vzroki smrti namreč niso dovolj točni, da bi bil izračun vzročno specifičnega opazovanega preživetja na populacijski ravni dovolj zanesljiv.

Relativno in čisto preživetje se izračunata s statističnim primerjanjem opazovanega preživetja proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki (t.i. pričakovano preživetje). Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Od leta 2014 naprej v letnih poročilih prikazujemo čisto preživetje izračunano po metodi Pohar-Perme, do takrat pa smo prikazovali preživetje izračunano po metodi Ederer-II, ki je ena od metod relativnega preživetja.

Opozarjamo še, da metoda čistega preživetja, uporabljena za izračun preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati preživetje na spletnem portalu SLORA. Na spletnem portalu SLORA prikazujemo opazovano preživetje in pa relativno preživetje izračunano po Hakulinenovi metodi.

Prebivalstvo Slovenije

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2015 so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	108.445	55.805	52.640
5–9	105.296	54.126	51.170
10–14	91.478	47.058	44.420
15–19	94.681	48.934	45.747
20–24	106.229	54.397	51.832
25–29	129.961	67.548	62.413
30–34	147.567	77.174	70.393
35–39	157.489	82.627	74.862
40–44	148.381	77.332	71.049
45–49	151.293	77.365	73.928
50–54	153.722	77.924	75.798
55–59	150.092	75.853	74.239
60–64	143.955	72.026	71.929
65–69	109.811	52.527	57.284
70–74	88.322	39.513	48.809
75–79	75.426	31.211	44.215
80+	100.929	31.134	69.795
Skupaj	2.063.077	1.022.554	1.040.523

Statistična regija	Skupaj	Moški	Ženske
Pomurska	116.434	57.283	59.151
Podravska	322.545	160.172	162.373
Koroška	71.218	35.755	35.463
Savinjska	254.237	127.134	127.103
Zasavska	57.567	28.340	29.227
Posavska	75.727	38.076	37.651
JV Slovenija	142.356	71.733	70.623
Osrednjeslovenska	535.375	261.490	273.885
Gorenjska	203.929	100.971	102.958
Primorsko-notranjska	52.551	26.557	25.994
Goriška	118.196	59.102	59.094
Obalno-Kraška	112.942	55.941	57.001
Slovenija	2.063.077	1.022.554	1.040.523

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2015.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2015.

Leta 2015 je v Sloveniji za rakom zbolelo 14.329 ljudi, 7.859 moških in 6.470 žensk. (Slika 1), umrlo pa 6.216 ljudi, 3.484 moških in 2.732 žensk. Od rojenih leta 2015 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (Tabela 5).

Konec decembra 2015 je živel 102.393 ljudi (46.168 moških in 56.225 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (Slika 1). Ocenjujemo, da je leta 2018 za rakom zbolelo več kot 15.000 prebivalcev Slovenije, približno 8.500 moških in 6.800 žensk. Ocene incidence za posamezne lokacije raka so prikazane v Tabeli 1 skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Ogroženost z rakom se zmerno veča in je največja v starejših letih; od vseh bolnikov z rakom je leta 2015 kar 62 % moških in 60 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (Slika 2). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še naprej večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v Tabeli 2 poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo za namene različnih primerjav uporabili tri standardne populacije svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – nemelanomski kožni, rak prostate, debelega črevesa in danke, dojke in pljuč – obsega 59 % vseh novih primerov rakavih bolezni (Slika 3). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 20 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu rak dojk, ki je predstavljal petino primerov vseh rakov pri ženskah (Slika 3).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 750 % pri moških in za 600 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 2,4 % letno, pri ženskah pa za 1,6 %. Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih večala povprečno za 1,0 % letno, pri ženskah pa za 1,1 % (Slika 4). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 0,3 % letno, pri ženskah pa za 0,6 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (Slika 4), v zadnjih 10-ih letih pri moških za 2,2 % letno, pri ženskah pa za 0,7 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, z izjemo kumulativne incidence, so statistično značilne pri stopnji tveganja 0,05.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000. Strmo pa pljučnega raka prehitelata rak prostate (povečanje za 4,2 % povprečno letno) in kožni nemelanomski rak (povečanje

za 5,2 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno že dosegli. Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (SVIT). Incidenca raka debelega črevesa in danke se je pri moških med leti 2006 in 2010 povečevala za 7,6 % letno, od leta 2010 do 2015 pa pada za 5,2 % letno. Pri ženskah se večajo incidenčne stopnje raka dojk (za 1,4 % povprečno letno), kože, razen melanoma (za 3,5 % povprečno letno), pljučnega raka (za 4,2 % povprečno letno) in raka materničnega telesa (za 2,5 % povprečno letno). Incidenčna stopnja raka materničnega vratu se od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu (ZORA) strmo manjša (za 3,4 % povprečno letno v zadnjih desetih letih). Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa SVIT spreminja časovni trend pojavljanja raka debelega črevesa in danke – med leti 2006 in 2010 se je incidenca povečevala za 3,9 % letno, od leta 2010 do 2015 pa pada za 4,5 % letno. Povprečne letne odstotne spremembe so prikazane ob krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2011–2015 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2006–2010). Pri moških se je skupno preživetje povečalo za 4,5 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje za več kot 4 odstotne točke. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Preživetje bolnic, zbolelih v obeh petletnih obdobjih, se ni bistveno spreminjalo in znaša 59 %.

Posebno pozornost v letošnjem poročilu posvečamo najpogostejšemu raku med slovenkami - raku dojk. Na *Sliki 7a* so prikazani rezultati mednarodne primerjave preživetij bolnic (raziskava Concord-3), ki so za rakom dojk zbolele med leti 2000 in 2014. Preživetje slovenskih bolnic, ki so zbolele v začetku tega tisočletja, je bilo slabše od evropskega povprečja. Razveseljivo pa je, da se je preživetje slovenskih bolnic, ki so zbolele med leti 2010 in 2014 močno približalo preživetjem bolnic iz najuspešnejših držav. *Slika 7b* prikazuje časovni trend incidenčnih stopenj po starostnih skupinah. Breme bolezni pri starejših od 70 let v zadnjih desetih letih ne narašča. Ugotavljamo pa, da se najhitreje večja število zbolelih pri mlajših od 50 let – v tej starosti ženske sicer redkeje zbolijo za rakom dojk, vendar pa se število novo zbolelih vsako leto poveča za 2,2 %. Po enakih starostnih skupinah je na *Sliki 7c* prikazan časovni trend preživetja slovenskih bolnic z rakom dojk. Petletno preživetje se pri vseh starostnih skupinah s časom izboljšuje. V zgodnejših letih, je bilo preživetje odvisno od starosti ob diagnozi, v zadnjih desetih letih pa ugotavljamo, da je petletno preživetje bolnic starih med 50 in 69 enako dobro kot pri tistih, ki zbolijo mlajše od 50 let.

Na *Slikah 7d in 7e* natančneje obravnavamo prav zbolele v starosti 50 do 69 let. V to starostno skupino je usmerjen tudi organiziran državni presejalni program za raka dojk DORA, ki na preventivno mamografijo vabi ženske vsake dve leti. Program DORA smo v Sloveniji začeli postopoma uvajati leta 2008, pokritost cele države pa smo zagotovili šele v začetku leta 2018. V obdobju 2011–2015, ki ga prikazujemo na *Slikah 7d in 7e*, je bilo s preventivno mamografijo v DORI odkritih približno četrtnina rakov dojk pri Slovenkah starih med 50 in 69 let. Med v DORI ugotovljenimi raki je imelo več bolnic natančno opredeljeno lokacijo tumorja, več je bilo tudi tistih s tumorjem v zgornjem zunanjem kvadrantu. Razlike v histoloških vrstah so nepomembne, je pa, pričakovano, v DORI veliko več bolnic diagnosticiranih z zgodnjim stadijem bolezni. Načini zdravljenja obeh skupin bolnic se ne razlikujejo bistveno, kljub v povprečju nižjim stadijem rakov ugotovljenih v DORI. Na *Sliki 7e* so prikazane razlike v preživetjih bolnic z rakom dojk glede na udeležbo v DORI ter stadij. Bolnice, ki niso bile vključene v presejalni program DORA in jim je bil tumor ugotovljen v višjih stadijih so imele izrazito slabše preživetje v primerjavi z bolnicami, ki so imele raka ugotovljenega v DORI. Za natančnejšo razjasnitev razlik v značilnostih bolezni, njihovega zdravljenja in izida bolezni povezanih z udeležbo v presejalnem programu DORA bo potrebna natančnejša analiza združenih podatkov Registra raka RS in Registra presejalnega programa DORA.

Podatki populacijskih registrov raka so v prvi vrsti namenjeni spremljanju populacijskih kazalnikov bremena raka, večinoma pa so premalo podrobni, da bi omogočali spremljanje kakovosti obravnave onkoloških bolnikov. Natančnejše podatke o diagnostiki in zdravljenju spremljajo t.i. klinični registri. Skladno z usmeritvami Državnega programa obvladovanja raka 2017–2021 bomo slovenskemu populacijskemu registru raka pridružili pet kliničnih registrov raka, med drugim tudi za raka dojk. Pilotno smo dodatne podatke o diagnostiki in zdravljenju slovenskih bolnic z rakom dojk, ki so zbolele leta 2013, zbrali v okviru mednarodne raziskave *High resolution project on prognosis and CARE of cancer patients (TRANSCAN / HIGHCARE)*; nekatere rezultate prikazujemo na *Slikah 7f in 7g*. *Slika 7g* povzema nekaj kazalnikov kakovosti obravnave slovenskih bolnic z rakom dojk, ki so zbolele leta 2013: v sklopu diagnostike pri nekaterih kazalnikih nismo dosegli ciljnih vrednosti. Precej slabši so kazalniki obravnave v kohorti bolnic, ki jim je bil rak dojk ugotovljen izven organiziranega presejalnega programa DORA. Zaznavamo tudi regijske razlike v času, ki je potreben, da se po postavitvi diagnoze prične specifično onkološko zdravljenje (*Slika 7f*).

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2015 pri 95,0 % od 14.329 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 4,7 % pa z drugimi preiskavami. Spodbudno je, da je že več let le 0,3 % primerov v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti; RRRS verjetno niso bili prijavljeni ker niso bili zdravljeni v bolnišnici zaradi starosti ali napredovale bolezni. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno

standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v številu in starostni strukturi prebivalcev. *Tabeli 6a* in *6b* smo v letošnjem poročilu razširili z nekaj dodatnimi lokacijami. V letu 2015 so se spremenile meje štirih statističnih regij (savinjske, posavske, osrednjeslovenske in zasavske), zato je potrebna pozornost pri primerjavi in interpretaciji podatkov iz prejšnjih let.

Kakšna je bila morfološka slika malignomov pri 13.619 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ekстранodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekстранodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi.

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov; objavljamo le podatke o prvem kurativnem zdravljenju. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2015. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

Uradne podatke o umrljivosti za rakom v letu 2015 prikazujemo v *Tabeli 13*; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora.

V *Tabeli 14* so prikazana 1-, 3- in 5-letna čista preživetja bolnikov zbolelih med leti 2011 in 2015.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj, podatke za vse kožne tumorje pa Agata Čampa, sodelavka Klinična registra kožnega melanoma.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Odgovore na vsa strokovna vprašanja nam priskrbijo zdravniki specialisti z Onkološkega inštituta Ljubljana. V prav posebno pomoč pa so vsi strokovni nasveti s področja patologije, ki nam jih že vrsto let nudi doc. dr. Matej Bračko, dr. med., specialist patologije, za letošnje letno poročilo pa nam je prijazno svetovala tudi dr. Gorana Gašljevič, dr. med., specialistka patologije.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. It was led by dr. Maja Primic Žakelj until 2018. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In 2003 a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the CRRS, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnostics, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentric studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the CRRS are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (here and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2018) are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, entitled *Cancer in Slovenia* in years 1965–1977 and 2007–2014, and *Cancer Incidence in Slovenia* in the period 1978–2006. Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the *Cancer Incidence in Five Continents* issued by the International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *CONCORD-1*, *CONCORD-2*, *CONCORD-3*, *RARECARE* and *EUNICE*.

In 2010, the CRRS's database has been upgraded and data processing modernized. At the same time an *interactive web portal* named SLOVA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAK/cancer". It is available at www.slora.si/en/. It enables a simple access to data on cancer in Slovenia collected by the CRRS (incidence, prevalence and survival; currently till 2015) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) as well as the comparisons with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment. Complementary sources of information are death certificates that we get from National Institute of Public Health of Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of pre-cancerous and early cancerous lesions of cervix uteri, DORA for early detection of breast cancer and SVIT for the detection of pre-cancerous lesions and cancer of colon and rectum. The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Where patients' data reported on notifications are not complete or adequate and where the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the CRRS's staff.

Calculation of patient prevalence and survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the percentage of the lost to follow-up in CRRS is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

Detailed analyses of the spatial distribution of cancer are enabled by accurately defined addresses of patients with cancer and regular connection to the Registry of Spatial Units of the Surveying and Mapping Authority. Table 6 shows cancer burden at the level of 12 statistical regions as in effect in Slovenia in 2015.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal CRRS guidelines.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8).

When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two being assigned to C96.7 and the polycythaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology

(third revision, 2011 update) follows this classification. Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used for solid tumors, classifying them into localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Stage according to TNM or any other appropriate classification is also stored in the CRRS database, if available. Gynecological tumors are thus defined also according to the FIGO classification and in skin melanoma size according to Clark's level and Breslow's thickness is registered. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of

patients in order to provide us with information about their vital status and among them we often find cases that have not been entered into the CRRS database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2018 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et al.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 inhabitants, while *crude mortality rate* is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) in the same period; it is expressed per 100,000 person-years. The age specific rate (incidence or mortality rate) is calculated in the same way, but for each age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (CR), (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 inhabitants. The cumulative rate can be interpreted as a form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed as a percentage. If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated as cumulative risk according to the following formula: $CRisk = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 7.8/100 can be used to estimate cumulative risk of breast cancer that is in this case 7.5%. This means that 7.5% of women born in 2018 (approximately one out of 13) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death.


Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons ever diagnosed with cancer and being alive at specific time date, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diagnoses.

Survival

In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. There are several options and methods for survival calculation. The basic and at the same time the simplest measure of survival is the so-called observed survival, where all deaths, also those



not caused by cancer, are included in the calculation. In order to evaluate the survival of cancer patients, which takes into account the cancer-specific deaths only, the methods of relative and net survival are used in population studies. The data on official causes of death are often insufficiently accurate for the calculation of the causal specific observed survival at the population level.

Relative and net survival are calculated by statistical comparison of the observed survival in the group of patients under study and survival with respect to gender and age over a certain period of time in the population the patients come from (i.e. the expected survival). The expected survival is calculated from general mortality data and is published routinely in the form of country specific life tables within the framework of its vital statistics; for our calculations, the Slovenian complete yearly life tables are used. Since 2014 net survival is presented in the annual reports. It is calculated using the Pohar-Perme method. In previous years we calculated survival with the Ederer-II approach, which is one of the methods of relative survival.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA. The SLORA web portal shows the observed survival and the relative survival computed by the Hakulinen method.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports the population data on July 1 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2015 by age and by sex are presented.

Age	Total	Males	Females
0–4	108,445	55,805	52,640
5–9	105,296	54,126	51,170
10–14	91,478	47,058	44,420
15–19	94,681	48,934	45,747
20–24	106,229	54,397	51,832
25–29	129,961	67,548	62,413
30–34	147,567	77,174	70,393
35–39	157,489	82,627	74,862
40–44	148,381	77,332	71,049
45–49	151,293	77,365	73,928
50–54	153,722	77,924	75,798
55–59	150,092	75,853	74,239
60–64	143,955	72,026	71,929
65–69	109,811	52,527	57,284
70–74	88,322	39,513	48,809
75–79	75,426	31,211	44,215
80+	100,929	31,134	69,795
Total	2,063,077	1,022,554	1,040,523

Population of Slovenia by age and by sex, July 1, 2015.

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard “statistical” definition.

Statistical region	Total	Males	Females
Pomurska	116.434	57.283	59.151
Podravska	322.545	160.172	162.373
Koroška	71.218	35.755	35.463
Savinjska	254.237	127.134	127.103
Zasavska	57.567	28.340	29.227
Posavska	75.727	38.076	37.651
JV Slovenija	142.356	71.733	70.623
Osrednjeslovenska	535.375	261.490	273.885
Gorenjska	203.929	100.971	102.958
Primorsko-notranjska	52.551	26.557	25.994
Goriška	118.196	59.102	59.094
Obalno-Kraška	112.942	55.941	57.001
Slovenia	2.063.077	1.022.554	1.040.523

Population by Slovenian statistical regions and by sex, July 1, 2015.

In 2015, 14,329 patients were diagnosed with cancer, 7,859 males and 6,470 females, and 6,216 patients died from cancer, 3,484 males and 2,732 females (*Figure 1*). From those born in 2015, one in two males and one in three females are expected to develop cancer by their age of 74 (*Table 5*).

At the end of December 2015, there were 102,393 people (46,168 males and 56,225 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated that in 2018 there were more than 15,000 Slovenian inhabitants newly diagnosed with cancer, approximately 8,500 males and 6,800 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2015, 62% males and 60% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will continue to increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For the purposes of different comparisons with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (non-melanoma skin, prostate, colorectal, lung and breast) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2015 was prostate (20.0% of all new cases). In females, breast cancer was the most frequent cancer site with one fifth of all new cases (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 750% in males and by 600% in females. In the last 10 years, the average annual increase in males was 2.4% and 1.6% in females. The increase in crude mortality rate in the last 10 years was on average 1.0% per year in males and 1.1% per years in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 0.3%, but 0.6% in females. Cumulative mortality rate is decreasing since 1985 in both sexes, in the last 10 years, in males on average by 2.2% and in females on average by 0.7% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer. All average annual changes with the exception of cumulative incidence are statistically significant at a risk level of 0.05.


The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (around 90/100.000). Lung cancer was finally overcome by prostate cancer (average increase by 4.2% per year) and by non-melanoma skin cancer (average increase by 5.2% per year).

The huge increase in prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. The data for the last few years show that the incidence peak of prostate cancer has been reached. Similarly, the changes in the colorectal cancer incidence should be interpreted taking into consideration the changes in the diagnostic practice – in Slovenia the National colorectal cancer screening programme (SVIT) has been introduced in 2009. The average annual increase in colorectal cancers in males in the period 2006–2010 was 7.6%, but there was an average annual decrease of 5.2% in the following years 2010–2015. In females, the incidence rate of breast (by 1.4% per year on average), lung (by 4.2% per year on average), non-melanoma skin (by 3.5% per year on average), and uterine cancer (by 2.5% per year on average) is increasing, while the incidence of cervical cancer is rapidly decreasing since the introduction of the National cervical cancer screening programme (ZORA); the average annual decrease in last ten years was 3.4%. Like in males also in females the colorectal cancer incidence time trends have been changed because the national screening programme SVIT has been introduced: in the period 2006–2010 the incidence raised for 3.9% annually, but in the years 2010–2015 it decreased by 4.5% annually. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2011–2015 is presented and compared to those diagnosed in 2006–2010. In males, the overall five-year relative survival increased for 4.5 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased for 4 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall survival in both time periods has not changed much and amounts to 59%.

In this year's report a special attention is given to the most common cancer among Slovenian women - breast cancer. *Figure 7a* shows the international comparison of survival rates for breast cancer patients diagnosed between 2000 and 2014 provided by Concord-3 study. The survival of Slovenian breast cancer patients diagnosed at the beginning of our millennium was below the European average. However, the survival of Slovenian patients who have been diagnosed between 2010 and 2014 has come close to the survival of patients from countries with highest survival. *Figure 7b* shows the time trends of Slovenian breast cancer incidence by age groups. The burden of disease in the elderly (70+) has not been increasing in the last ten years. On the contrary, the incidence in younger patients (below 50 at diagnosis) is increasing by 2.2% every year. Applying the same age groups, *Figure 7c* presents survival time trends of Slovenian breast cancer patients. Five-year net survival improves over time in all age groups. In earlier years, survival was dependent on age at diagnosis, but over the past ten years, the five-year net survival of patients aged 50 to 69 is as high as in those younger than 50 years at diagnosis.

Figures 7d and *7e* present the breast cancer patients aged 50 to 69 at diagnosis. An organized national screening programme for breast cancer DORA is also targeting



this age group. The DORA programme was introduced in part of Slovenian population already in 2008, but it is available population-wide only from 2018. In the period 2011–2015, which is presented in *Figures 7d* and *7e*, approximately one quarter of all breast cancers in Slovenian women aged 50 to 69 was detected by DORA preventive mammography. The exact tumour location is more often defined in DORA detected cancers; there were also more tumours located in the upper outer breast quadrant. Differences in histological types are insignificant. However, as expected, much more DORA patients are diagnosed with an early stage of the disease. Despite more favourable stage distribution in DORA detected patients, the treatment modalities of both groups do not differ significantly. *Figure 7e* shows the differences in the survival of breast cancer patients with regard to participation in DORA and stage. Patients with breast cancer who were not detected in the DORA screening program and who had been diagnosed with tumours at higher stages had significantly worse survival than those patients with breast cancer detected in DORA. For a more detailed clarification of the differences in the characteristics of the disease, treatment and the outcomes associated with participation in the DORA screening program, a more detailed analysis of the combined data of the Cancer Registry of the Republic of Slovenia and the DORA screening registry will be needed.

The data in population-based cancer registries are collected to monitor population cancer burden indicators. In general, they are insufficiently detailed to allow monitoring of the quality of care of oncological patients. More detailed diagnostic and treatment data are available by clinical registers. Following the National Cancer Control Plan 2017–2021, five clinical cancer registries, including breast cancer clinical registry, will be added to the Slovenian general Cancer Registry. As a pilot for breast cancer clinical registry, additional data on the diagnosis and treatment of Slovenian breast cancer patients diagnosed in 2013 were collected in the framework of the international study *High resolution project on prognosis and CARE of cancer patients (TRANSCAN / HIGHCARE)*; some of its results are shown in *Figures 7f* and *7g*. *Figure 7g* summarizes selected quality of care indicators for the Slovenian breast cancer patients diagnosed in 2013: for certain indicators target values have not been achieved. Even more, the quality of care indicators in the DORA detected cases are superior compared to others. In addition, the are regional differences in the time from diagnosis to the treatment outset (*Figure 7g*).

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2015, in 95.0% from 14,329 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 4.7% with other investigations. It is encouraging that for several years only 0.3% of cases in the CRRS were registered from death certificates only. They were probably not reported to CRRS because they represent the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different number and age structure

of population in these regions. In 2015 the borders of four statistical regions changed (Savinjska, Posavska, Osrednjeslovenska and Zasavska) so the comparison and interpretation of data from previous years needs to be done carefully.

The morphology of tumours in 13.619 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extra nodal sites, only the absolute numbers are given.

Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization.

Table 11 presents basic data on cancer patients' primary curative treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b and 11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at the Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 12*, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2015 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years).

In *Table 13*, there are official data on cancer mortality in 2015. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (<http://www.slora.si/en/>).

Table 14 shows 1-, 3-, 5-, and 10-years net survival of patients diagnosed between 2011 and 2015.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other healthcare institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought and completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Maruška Ferjančič and Mrs. Polona Škulj from the Institute of Oncology's Hospital Registry. Data for melanoma and non-melanoma skin cancers were provided by Mrs. Agata Čampa from the Slovenian Melanoma Clinical Registry.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

Answers to all expert questions are provided by clinical specialists from the Institute of Oncology Ljubljana. Expert advice in the field of pathology is especially helpful, and has been offered to us for many years by pathology specialist, assist. prof. dr. Matej Bračko, MD. For the current Annual Report additional guidance in pathology was provided by pathology specialist dr. Gorana Gašljević, MD.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: <http://ci5.iarc.fr>.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCORE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCORE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; 15: 23–34
- Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999–2007: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2014;15: 35-47.
- Coleman, MP, Quaresma, M, Berrino, F..., and the CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*. 2008; 9: 730–756
- Allemani C, Weir HK, Carreira H . . . and the CONCORD Working Group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015; 385: 977-1010.

- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšič M and CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018; 391: 1023-75.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47; 2493–511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. *Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. *Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. *Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997)*. Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia)*. Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Uredba komisije (EU) št. 1319/2013 o spremembi priloge k Uredbi (ES) št. 1059/2003 Evropskega parlamenta in Sveta o oblikovanju skupne klasifikacije statističnih teritorialnih enot (NUTS)
- Savezni zavod za zdravstveno zaščito. *Međunarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija*. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. *Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems)*. Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. *International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition)*. Geneva: WHO Press, 2011.
- World Health Organisation. *International classification of diseases for Oncology. 3rd Edition*. Geneva: World Health Organisation, 2000.
- World Health Organisation. *International Classification of Diseases for Oncology, Third Edition, First Revision*. Geneva: World Health Organization, 2013.
- Swerdlow SH., Campo E, Harris NL et al, eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2*. Geneva: World Health Organization, 2008.
- Jensen OM, Parkin M et al, eds. *Cancer registration: principles and methods*. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. *Cancer epidemiology: principles and methods*. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. *Stat Med* 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014.
URL: <http://pxweb.stat.si/>.
- Dyba T, Hakulinen T, Päiväranta L. A simple non-linear model in incidence prediction. *Statistics in Medicine* 16: 2297–309, 1997.
- Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Statistics in medicine* 2000; 19(3): 335–51.
- Pohar M, Stare J. Relative survival analysis in R. *Computer Methods and Programs in Biomedicine* 2006; 81: 272–8.
- Perme MP, Stare J, Estève J. On estimation in relative survival. *Biometrics*. 2012;68(1):113-20.
- Žagar T. *Lifetables for Slovenia 1982–2007*. Rostock: Max Planck, 2008.
URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.
- Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B et al. Quality indicators in breast cancer care. *Eur J Cancer* 2010; 46: 2344-56.
- Projekt TRANSCAN/HIGHCARE: www.transcanfp7.eu/index.php/abstract/highcare.html.


Slika 1: Breme raka, Slovenija 2015.

Figure 1: Cancer burden, Slovenia 2015.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2015.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2015.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2015.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2015.



MOŠKI IN ŽENSKÉ / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danko / Colorectum (C18–C20)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2015.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2015.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2015.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2015.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level


Slika 6: Pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2006–2010 in 2011–2015 po spolu in pri obeh spolih skupaj.

Figure 6: Five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2006–2010 and 2011–2015 by sex and for both sexes together.




Slika 6: Nadaljevanje.
Figure 6: Continued.

ŽENSKE / FEMALES




Slika 6: Nadaljevanje.
Figure 6: Continued.




Slika 7a: Rak dojke - starostno standardizirana pet-letna čista preživetja pri odraslih ženskah (15–99 let) po evropskih državah in obdobjih diagnoze 2000–2014: raziskava Concord-3.

Figure 7a: Breast cancer – age-standardised five-year net survival in women (15–99 years), by European countries and calendar period of diagnosis 2000–2014: Concord-3 study.




Slika 7b: Časovni trend starostno specifičnih incidenčnih stopenj raka dojk pri ženskah s povprečno letno spremembo za zadnjih 10 let, Slovenija 1961–2015.

Figure 7b: Time trend of age specific incidence rate of breast cancer (women) with average annual change in last 10 years, Slovenia 1961–2015.



Slika 7c: Časovni trend pet-letnega čistega preživetja bolnic z rakom dojk po starostnih skupinah, Slovenija 1985–2015.

Figure 7c: Time trend of five-year net survival of breast cancer (women) by age group, Slovenia 1985–2015.




Slika 7d: Bolnice z rakom dojke stare med 50 in 69 let glede na udeležbo v presejalnem programu DORA po lokaciji, histološki vrsti, stadiju in načinu prvega zdravljenja, Slovenija 2011–2015.

Figure 7d: Breast cancer (women aged 50–69 years) according to attendance in organised screening programme DORA by site, histological type, stage and first curative treatment, Slovenia 2011–2015.

		Vsi med 50 in 69 let All between 50 and 69 years		Ugotovljen v programu DORA Diagnosed in programme DORA		Ni ugotovljen v programu DORA Not diagnosed in programme DORA	
		Število Number	%	Število Number	%	Število Number	%
	Vsi /All	3467	100,0	873	100,0	2594	100,0
	Dojka, in situ (D05) / Breast, in situ	367	10,6	185	21,2	182	7,0
	Dojka, invazivni (C50) / Breast, invasive	3100	89,4	688	78,8	2412	93,0
	Samo invazivni (C50) / Invasive only	3100	100,0	688	100,0	2412	100,0
Šifra MKB ICD code	C50.0 Bradavica in areola / Nipple and areola	16	0,5	2	0,3	14	0,6
	C50.1 Osrednji del dojke / Central portion of breast	149	4,8	42	6,1	107	4,4
	C50.2 Zgornji-notranji kvadrant dojke / Upper-inner quadrant of breast	182	5,9	49	7,1	133	5,5
	C50.3 Spodnji-notranji kvadrant dojke / Lower-inner quadrant of breast	94	3,0	33	4,8	61	2,5
	C50.4 Zgornji-zunanji kvadrant dojke / Upper-outer quadrant of breast	765	24,7	263	38,2	502	20,8
	C50.5 Spodnji-zunanji kvadrant dojke / Lower-outer quadrant of breast	175	5,6	49	7,1	126	5,2
	C50.6 Pazdušni predel dojke / Axillary tail of breast	19	0,6	0	0,0	19	0,8
	C50.8 Praraščajoča lezija dojke / Overlapping sites of breast	211	6,8	52	7,6	159	6,6
	C50.9 Dojka, neopredeljena / Breast of unspecified site	1489	48,0	198	28,8	1291	53,5
Histološka vrsta Histological type	Carcinoma, NOS	62	2,0	1	0,1	61	2,5
	Adenocarcinoma, NOS	31	1,0	0	0,0	31	1,3
	Mucinous adenocarcinoma	43	1,4	8	1,2	35	1,5
	Infiltrating duct carcinoma, NOS	2369	76,4	532	77,3	1837	76,2
	Intraductal papillary adenocarcinoma	37	1,2	11	1,6	26	1,1
	Intracystic carcinoma, NOS	12	0,4	3	0,4	9	0,4
	Intraductal micropapillary carcinoma	13	0,4	3	0,4	10	0,4
	Medullary carcinoma, NOS	19	0,6	4	0,6	15	0,6
	Lobular carcinoma, NOS	349	11,3	87	12,6	262	10,9
	Infiltrating duct and lobular carcinoma	47	1,5	16	2,3	31	1,3
	Infiltrating duct mixed with other types of carcinoma	38	1,2	8	1,2	30	1,2
	Other specified	80	2,6	15	2,2	65	2,7
UICC stadij UICC stage	IA	1288	41,5	414	60,2	874	36,2
	IB	113	3,6	36	5,2	77	3,2
	IIA	700	22,6	137	19,9	563	23,3
	IIB	308	9,9	41	6,0	267	11,1
	IIIA	220	7,1	30	4,4	190	7,9
	IIIB	72	2,3	3	0,4	69	2,9
	IIIC	176	5,7	21	3,1	155	6,4
	IV	178	5,7	4	0,6	174	7,2
	Neznano / Unknown	45	1,5	2	0,3	43	1,8
Način prvega zdravljenja First curative treatment	Samo kirurgija / Surgery only	90	2,9	15	2,2	75	3,1
	Kirurgija in sistemska zdravljenje / Surgery and systemic therapy	670	21,6	151	21,9	519	21,5
	Kirurgija in obsevanje / Surgery and radiotherapy	112	3,6	14	2,0	98	4,1
	Kirurgija, sistemska zdravljenje in obsevanje / Surgery, systemic therapy and radiotherapy	2003	64,6	495	71,9	1508	62,5
	Sistemska zdravljenje in obsevanje / Systemic therapy and radiotherapy	71	2,3	1	0,1	70	2,9
	Samo obsevanje / Radiotherapy only	2	0,1	1	0,1	1	0,0
	Samo sistemska zdravljenje / Systemic therapy only	98	3,2	3	0,4	95	3,9
	Brez zdravljenja / No treatment	54	1,7	8	1,2	46	1,9


Slika 7e: Pet-letno čisto preživetje bolnic z rakom dojke starih 50–69 let glede na udeležbo v presejalnem programu DORA, Slovenija 2011–2015.

Figure 7e: Five-year net survival of breast cancer (women aged 50–69 years) according to attendance in organised screening programme DORA, Slovenia 2011–2015.



Slika 7f: Čas do prvega zdravljenja (operacija, sistemska terapija ali obsevanje) pri bolnicah z rakom dojke po statističnih regijah, Slovenija 2013.

Figure 7f: Time to first treatment (surgery, systematic treatment or radiotherapy) in breast cancer patients by statistical regions, Slovenia 2013.



Slika 7g: Definicije in stopnje doseganja izbranih kazalnikov kakovosti oskrbe bolnic z rakom dojk*, Slovenija 2013.

Figure 7g: Definitions and adherence rates of selected breast cancer care quality indicators*, Slovenia 2013.

EUSOMA ID	Kazalnik Indicator	Minimalni standard Minimum standard (%)	Cilj Target (%)	Slovenija 2013 Slovenia 2013 (%)
4a	Delež invazivnih rakov, pri katerih so zabeleženi naslednji napovedni dejavniki: histološka vrsta, stopnja diferenciacije, ER, PgR, HER2 Proportion of invasive cancer cases for which the following prognostic/predictive parameters have been recorded: histological type, grading, ER&PgR, HER2	90	95	90
4b	Delež primarno operiranih invazivnih rakov, pri katerih so zabeleženi naslednji napovedni dejavniki: histološka vrsta, stopnja diferenciacije, ER, PgR, HER2, patološki stadij (T in N), velikost invazivne komponente v mm, peritumorska vaskularna invazija Proportion of invasive cancer cases with primary surgery, for which the following prognostic/predictive parameters have been recorded: histological type, grading, ER & PR, HER2, pathological stage (T and N), size in mm for the invasive component, peritumoral vascular invasion	95	98	89
9c	Delež bolnic z invazivnim rakom in klinično negativnimi pazdušnimi bezgavkami (+US ±FNA/CNB), pri katerih je bila opravljena biopsija varovalne bezgavke Proportion of patients (invasive cancers) and a clinically negative axilla (+US ±FNA/CNB) who had sentinel lymph-node biopsy	90	95	89
10a	Delež bolnic z invazivnim rakom brez oddaljenih metastaz, ki so bile po kirurški resekciji tumorja in ustreznih zamejitvi/disekciji pazdušnih bezgavk obsevane Proportion of patients (invasive cancer M0) who received postoperative radiotherapy after surgical resection of the primary tumour and appropriate axillary staging/surgery in the framework of BCT	90	95	92
10b	Delež bolnic z boleznijo, razširjeno v pazdušne bezgavke (≥pN2a), ki so bile po mastektomiji obsevane Proportion of patients with involvement of axillary lymph nodes (≥pN2a) who received post-mastectomy radiotherapy	90	95	90
11a	Delež bolnic z invazivnim rakom, velikim do 3 cm (celotna velikost, vključujoč DCIS komponento), pri katerih je bila opravljena ohranitvena operacija Proportion of patients with invasive breast cancer not greater than 3 cm (total size, including DCIS component) who underwent BCT	70	80	71
11d	Delež bolnic z invazivnim rakom in pN0, ki niso bile deležne radikalne odstranitve pazdušnih bezgavk Proportion of invasive breast cancer patients with pN0 who do not undergo axillary clearance	80	90	94
12a	Delež bolnic s hormonsko odvisnim (samo ER+) invazivnim rakom, ki so prejele hormonsko terapijo, med vsemi hormonsko odzivnimi bolnicami Proportion of patients with endocrine sensitive (ER+ only) invasive carcinoma who received hormone therapy, out of the total number of patients with this diagnosis	80	90	94
12b	Delež bolnic z ER- in PgR- rakom, ki niso prejele adjuvantne hormonske terapije, med vsemi bolnicami z enako diagnozo Proportion of patients with ER- and PgR- carcinoma who did not receive adjuvant hormone therapy out of the total number of patients with the same diagnosis	98	100	100
13a	Delež bolnic z ER- invazivnim karcinomom in T > 1 cm ali N+, ki so prejele adjuvantno kemoterapijo, med vsemi bolnicami z enako diagnozo Proportion of patients with ER- (T > 1 cm or Node+) invasive carcinoma who received adjuvant chemotherapy, out of the total number of patients with the same diagnosis	80	90	83
13b	Delež bolnic z invazivnim karcinomom N+ ali N- pri T > 1 cm ter HER2+ (IHC 3+ ali FISH+), ki so prejele adjuvantno kemoterapijo in adjuvantni trastuzumab, med vsemi bolnicami z enako diagnozo Proportion of patients with N+ or N- T > 1 cm HER2+ (IHC 3+ or in situ hybridisation positive FISH +) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab, out of the total number of patients with the same diagnosis	80	90	87
13c	Delež bolnic s HER2 negativnim invazivnim karcinomom, ki niso prejele adjuvantnega trastuzumaba, med vsemi bolnicami z enako diagnozo Proportion of patients with HER2 negative invasive carcinoma who did not have adjuvant trastuzumab, out of the total number of patients with the same diagnosis	98	100	100
13e	Delež bolnic z vnetnim rakom dojk ali lokalno napredovalim neresektibilnim ER- karcinomom, ki niso prejele neoadjuvantne kemoterapije, med vsemi bolnicami z enako diagnozo Proportion of patients with inflammatory breast cancer (IBC) or locally advanced non-resectable ER- carcinoma who had neoadjuvant chemotherapy over the total of patients with the same diagnosis	90	95	83

Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2006–2015 in 2018.

Table 1: Observed and estimated cancer incidence, Slovenia 2006–2015 and 2018.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2006–2010		Povprečne letne opazovane vrednosti 2011–2015		Ocena za 2018			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Estimation for 2018			
			Povprečne letne opazovane vrednosti 2006–2010		Average annual observed values 2011–2015		Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
Number		Incidence rate per 100,000		Number		Incidence rate per 100,000		Incidence rate per 100,000 (95% prediction interval)		
C00–C96	Vse lokacije All sites	M+Ž	12378	610,1	13824	671,5	15301	14951–15651	740	723–757
		M	6614	660,5	7566	742,2	8508	8252–8764	828	803–853
		Ž	5764	560,9	6258	602,2	6793	6554–7032	653	630–676
C00–C14	Usta in žrelo Mouth and pharynx	M	275	27,4	272	26,6	288	242–333	28	24–32
		Ž	68	6,6	72	6,9	76	53–100	7	5–10
C15	Požiralnik Oesophagus	M	69	6,9	76	7,5	80	55–104	8	5–10
		Ž	16	1,6	16	1,5	17	6–28	2	1–3
C16	Želodec Stomach	M	286	28,6	297	29,1	298	252–343	29	25–33
		Ž	181	17,6	175	16,9	167	133–200	16	13–19
C18	Debelo črevo Colon	M	475	47,4	496	48,7	509	435–583	50	42–57
		Ž	377	36,6	376	36,2	383	329–437	37	32–42
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	394	39,4	381	37,3	362	313–412	35	30–40
		Ž	255	24,8	213	20,5	185	151–220	18	15–21
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	115	11,5	149	14,6	174	140–208	17	14–20
		Ž	49	4,8	50	4,8	55	35–74	5	3–7
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	64	6,4	78	7,6	90	65–116	9	6–11
		Ž	102	9,9	105	10,1	108	80–136	10	8–13
C25	Trebušna slinavka Pancreas	M	161	16,1	191	18,8	214	175–253	21	17–25
		Ž	166	16,1	182	17,5	201	164–239	19	16–23
C32	Grlo Larynx	M	99	9,9	87	8,5	81	56–106	8	5–10
		Ž	10	1,0	12	1,1	12	2–22	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	892	89,1	893	87,6	897	815–979	87	79–95
		Ž	345	33,6	420	40,5	510	452–568	49	43–55
C43	Malignni melanom kože Malignant melanoma of skin	M	215	21,5	274	26,9	335	288–383	33	28–37
		Ž	239	23,2	248	23,9	259	217–302	25	21–29
C44	Druge maligne neoplazme kože Skin, other malignomas	M	955	95,3	1258	123,4	1583	1478–1687	154	144–164
		Ž	1027	99,9	1231	118,5	1423	1324–1521	137	127–146
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	27	2,7	31	3,1	32	21–44	3	2–4
		Ž	37	3,6	42	4,0	43	26–60	4	2–6
C50	Dojka Breast	M	9	0,9	13	1,2	16	5–27	2	0–3
		Ž	1183	115,1	1273	122,5	1365	1269–1462	131	122–141
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	144	14,0	123	11,9	106	82–131	10	8–13
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	292	28,4	332	32,0	374	324–425	36	31–41
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	173	16,9	161	15,5	149	118–181	14	11–17
C61	Prostata Prostate	M	1242	123,9	1540	151,1	1838	1717–1959	179	167–191
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	102	10,2	113	11,0	119	92–147	12	9–14
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	217	21,7	245	24,0	273	228–317	27	22–31
		Ž	111	10,8	130	12,5	154	122–187	15	12–18
C67	Sečni mehur Bladder	M	201	20,1	245	24,0	280	234–325	27	23–32
		Ž	77	7,5	85	8,1	93	68–119	9	6–11
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	83	8,3	88	8,7	98	72–124	10	7–12
		Ž	63	6,1	70	6,7	84	60–108	8	6–10
C73	Ščitnica Thyroid gland	M	32	3,2	46	4,5	61	14–108	6	1–11
		Ž	120	11,7	124	11,9	137	107–167	13	10–16
C81	Hodgkinova bolezen Hodgkin's disease	M	29	2,9	21	2,1	22	10–34	2	1–3
		Ž	23	2,2	24	2,3	30	15–44	3	1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	137	13,7	196	19,2	261	219–302	25	21–29
		Ž	140	13,7	193	18,5	228	119–338	22	11–32
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	67	6,7	64	6,3	60	40–80	6	4–8
		Ž	60	5,8	64	6,1	66	44–88	6	4–8
C91–C95	Levkemije Leukaemias	M	154	15,4	167	16,4	175	139–211	17	14–21
		Ž	117	11,4	126	12,1	135	105–166	13	10–16

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2015.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	14329	694,6	336,9	478,9	569,2
		M	7859	768,6	399,6	581,9	704,5
		Ž	6470	621,8	289,6	403,9	471,7
C00–C14	Usta in žrelo Mouth and pharynx	M	286	28,0	16,0	22,2	24,9
		Ž	73	7,0	3,8	5,0	5,6
C15	Požiralnik Oesophagus	M	70	6,8	3,6	5,2	6,0
		Ž	23	2,2	1,0	1,4	1,7
C16	Želodec Stomach	M	297	29,0	14,4	21,7	26,8
		Ž	159	15,3	5,7	8,7	10,5
C18	Debelo črevo Colon	M	471	46,1	23,0	34,5	42,6
		Ž	382	36,7	14,1	21,1	25,7
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	313	30,6	15,6	23,0	28,1
		Ž	187	18,0	6,9	10,4	12,7
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	163	15,9	8,3	12,0	14,3
		Ž	51	4,9	1,7	2,7	3,4
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	77	7,5	3,4	5,5	7,0
		Ž	104	10,0	3,4	5,3	6,6
C25	Trebušna slinavka Pancreas	M	192	18,8	9,2	14,0	17,1
		Ž	199	19,1	6,8	10,4	13,0
C32	Grlo Larynx	M	83	8,1	4,4	6,2	7,0
		Ž	7	0,7	0,3	0,4	0,4
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	978	95,6	48,0	71,2	85,4
		Ž	460	44,2	20,3	29,0	33,2
C43	Maligni melanom kože Malignant melanoma of skin	M	290	28,4	16,4	22,6	26,6
		Ž	245	23,5	13,1	17,2	19,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1397	136,6	66,5	101,4	125,5
		Ž	1282	123,2	48,5	71,5	87,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	36	3,5	2,2	2,8	3,3
		Ž	42	4,0	2,4	2,9	3,2
C50	Dojka Breast	M	8	0,8	0,4	0,6	0,7
		Ž	1319	126,8	69,4	93,6	105,7
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	119	11,4	7,4	9,4	10,3
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	355	34,1	16,5	23,4	26,9
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	151	14,5	7,9	10,6	11,8
C61	Prostata Prostate	M	1599	156,4	78,3	115,9	142,3
		Ž	–	–	–	–	–
C62	Modo Testis	M	144	14,1	13,1	13,8	14,9
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	241	23,6	12,5	18,1	21,9
		Ž	120	11,5	5,2	7,3	8,5
C67	Sečni mehur Bladder	M	249	24,4	11,1	17,6	22,2
		Ž	88	8,5	3,3	4,9	5,9
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	102	10,0	6,2	8,1	9,3
		Ž	77	7,4	4,4	5,4	5,9
C73	Ščitnica Thyroid gland	M	55	5,4	3,7	4,5	5,0
		Ž	150	14,4	10,0	12,2	13,6
C81	Hodgkinova bolezen Hodgkin's disease	M	29	2,8	2,9	2,8	3,0
		Ž	20	1,9	1,7	1,8	2,0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	217	21,2	11,3	16,2	19,6
		Ž	206	19,8	8,2	11,9	14,2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	5,8	2,9	4,4	5,4
		Ž	58	5,6	2,0	3,1	3,8
C91–C95	Levkemije Leukaemias	M	168	16,4	9,3	12,8	15,2
		Ž	141	13,6	7,6	9,3	10,5

* SSS – starostno standardizirana incidenčna stopnja na 100.000

** ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2015.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	14329	13619	95,0	668	4,7	42	0,3
		M	7859	7491	95,3	343	4,4	25	0,3
		Ž	6470	6128	94,7	325	5,0	17	0,3
C00	Ustnica Lip	M	14	14	–	0	–	0	–
		Ž	14	14	–	0	–	0	–
C01	Baza jezika Base of tongue	M	21	21	100	0	0	0	0
		Ž	7	7	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	29	29	100	0	0	0	0
		Ž	3	3	–	0	–	0	–
C03	Dlesen Gum	M	9	9	–	0	–	0	–
		Ž	5	5	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	28	28	100	0	0	0	0
		Ž	6	6	–	0	–	0	–
C05	Nebo Palate	M	14	14	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	12	–	0	–	0	–
		Ž	7	7	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	8	8	–	0	–	0	–
		Ž	6	6	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C09	Tonzila Tonsil	M	43	43	100	0	0	0	0
		Ž	10	10	–	0	–	0	–
C10	Orofarinks Oropharynx	M	35	35	100	0	0	0	0
		Ž	6	6	–	0	–	0	–
C11	Nazofarinks Nasopharynx	M	8	8	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C12	Piriformni sinus Pyramiform sinus	M	41	41	100	0	0	0	0
		Ž	1	1	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	24	24	100	0	0	0	0
		Ž	4	4	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	70	67	95,7	2	2,9	1	1,4
		Ž	23	21	91,3	2	8,7	0	0
C16	Želodec Stomach	M	297	291	98,0	5	1,7	1	0,3
		Ž	159	155	97,5	3	1,9	1	0,6
C17	Tanko črevo Small intestine	M	18	18	100	0	0	0	0
		Ž	18	17	94,4	1	5,6	0	0
C18	Debelo črevo Colon	M	471	454	96,4	15	3,2	2	0,4
		Ž	382	356	93,2	26	6,8	0	0
C19	Rektosigmoidna zveza Rectosigmoid junction	M	65	65	100	0	0	0	0
		Ž	47	46	97,9	1	2,1	0	0
C20	Rektum Rectum	M	248	245	98,8	3	1,2	0	0
		Ž	140	133	95,0	7	5,0	0	0
C21	Anus in analni kanal Anus and anal canal	M	3	3	–	0	–	0	–
		Ž	13	13	–	0	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	163	102	62,6	59	36,2	2	1,2
		Ž	51	32	62,7	19	37,3	0	0
C23	Žolčnik Gallbladder	M	23	16	69,6	7	30,4	0	0
		Ž	37	27	73,0	10	27,0	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	36	66,7	18	33,3	0	0
		Ž	67	38	56,7	29	43,3	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	192	136	70,8	56	29,2	0	0
		Ž	199	117	58,8	82	41,2	0	0
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	2	—	0	—	1	—
		Ž	2	0	—	1	—	1	—
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	7	7	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	4	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C32	Grlo Larynx	M	83	83	100	0	0	0	0
		Ž	7	7	—	0	—	0	—
C33	Sapnik Trachea	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	976	902	92,4	68	7,0	6	0,6
		Ž	458	423	92,4	35	7,6	0	0
C37	Timus Thymus	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	4	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	5	5	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C41	Kosti, sklepi hrustanec, druge Bone and articular cartilage of other and unspecified parts	M	7	7	—	0	—	0	—
		Ž	5	4	—	1	—	0	—
C43	Malignni melanom kože Malignant melanoma of skin	M	290	290	100	0	0	0	0
		Ž	245	245	100	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1397	1395	99,9	2	0,1	0	0
		Ž	1282	1281	99,9	1	0,1	0	0
C45	Mezoteliom Mesothelioma	M	30	30	100	0	0	0	0
		Ž	9	9	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	3	3	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	5	—	0	—	0	—
		Ž	17	16	94,1	1	5,9	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	31	31	100	0	0	0	0
		Ž	25	25	100	0	0	0	0
C50	Dojka Breast	M	8	8	—	0	—	0	—
		Ž	1319	1309	99,2	6	0,5	4	0,3
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—
		Ž	58	58	100	0	0	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—
		Ž	10	10	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—
		Ž	119	119	100	0	0	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—
		Ž	355	354	99,7	1	0,3	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—
		Ž	16	14	87,5	0	0	2	12,5
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—
		Ž	151	142	94,0	6	4,0	3	2,0

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—
		Ž	36	34	94,4	2	5,6	0	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—
		Ž	2	2	—	0	—	0	—
C60	Penis Penis	M	18	18	100	0	0	0	0
		Ž	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1599	1546	96,7	43	2,7	10	0,6
		Ž	—	—	—	—	—	—	—
C62	Modo Testis	M	144	143	99,3	1	0,7	0	0
		Ž	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	1	—	0	—	0	—
		Ž	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	227	204	89,9	23	10,1	0	0
		Ž	105	94	89,5	11	10,5	0	0
C65	Ledvični meh Renal pelvis	M	14	14	—	0	—	0	—
		Ž	15	13	86,7	2	13,3	0	0
C66	Sečevod Ureter	M	2	2	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C67	Sečni mehur Bladder	M	249	247	99,2	2	0,8	0	0
		Ž	88	84	95,5	3	3,4	1	1,1
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	1	—	1	—	0	—
		Ž	0	0	—	0	—	0	—
C69	Okoli očesni adneksi Eye and adnexa	M	14	14	—	0	—	0	—
		Ž	15	13	86,7	2	13,3	0	0
C70	Meninge Meninges	M	3	3	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C71	Možgani Brain	M	98	90	91,8	8	8,2	0	0
		Ž	75	58	77,3	17	22,7	0	0
C72	Hrbtne možgane, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	1	1	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	55	55	100	0	0	0	0
		Ž	150	150	100	0	0	0	0
C74	Nadledvična žleza Adrenal gland	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	4	3	—	1	—	0	—
		Ž	11	2	—	8	—	1	—
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	19	19	100	0	0	0	0
		Ž	13	12	—	1	—	0	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	26	17	65,4	9	34,6	0	0
		Ž	53	33	62,3	20	37,7	0	0
C79	Metastaze, drugje Metastases of other sites	M	11	5	—	6	—	0	—
		Ž	11	8	—	1	—	2	—
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	63	48	76,2	14	22,2	1	1,6
		Ž	63	35	55,6	26	41,3	2	3,2
C81	Hodgkinova bolezen Hodgkin's disease	M	29	29	100	0	0	0	0
		Ž	20	20	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	57	57	100	0	0	0	0
		Ž	60	60	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	138	138	100	0	0	0	0
		Ž	120	120	100	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	17	17	100	0	0	0	0
		Ž	16	16	100	0	0	0	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	5	5	—	0	—	0	—
		Ž	10	10	—	0	—	0	—
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	59	100	0	0	0	0
		Ž	58	58	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	16	16	100	0	0	0	0
		Ž	13	13	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	67	66	98,5	0	0	1	1,5
		Ž	44	44	100	0	0	0	0
C92	Mieločna levkemija Myeloid leukaemia	M	64	64	100	0	0	0	0
		Ž	62	62	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	2	2	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	16	16	100	0	0	0	0
		Ž	16	16	100	0	0	0	0
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	3	3	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	88	88	100	0	0	0	0
		Ž	94	94	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	96	96	100	0	0	0	0
		Ž	102	102	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	0	0	—	0	—	0	—
		Ž	103	103	100	0	0	0	0
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III)	M	—	—	—	—	—	—	—
		Ž	1154	1154	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	158	158	100	0	0	0	0
		Ž	47	47	100	0	0	0	0
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	28	22	78,6	6	21,4	0	0
		Ž	77	63	81,8	14	18,2	0	0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	47	47	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	9	5	—	4	—	0	—
		Ž	7	2	—	5	—	0	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2015.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	14329	24	14	8	30	41	87	145	216	322	558	898	1290	1981	1927	2071	1978	2739
		M	7859	6	10	4	19	26	49	64	94	122	242	436	729	1193	1195	1290	1132	1248
		Ž	6470	18	4	4	11	15	38	81	122	200	316	462	561	788	732	781	846	1491
C00	Ustnica Lip	M	14	0	0	0	0	0	0	0	0	0	0	2	1	2	2	3	0	4
		Ž	14	0	0	0	0	0	0	0	0	0	0	0	1	1	0	5	1	0
C01	Baza jezika Base of tongue	M	21	0	0	0	0	0	0	0	0	0	4	5	7	2	2	0	0	1
		Ž	7	0	0	0	0	0	0	0	0	2	0	1	2	0	1	1	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	29	0	0	0	0	0	0	0	0	3	3	4	4	3	5	4	3	0
		Ž	3	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1
C03	Dlesen Gum	M	9	0	0	0	0	0	0	0	0	0	1	0	2	2	0	1	2	1
		Ž	5	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	2
C04	Ustno dno Floor of mouth	M	28	0	0	0	0	0	0	0	0	0	3	5	5	5	3	4	3	0
		Ž	6	0	0	0	0	0	0	0	0	0	1	0	0	2	1	2	0	0
C05	Nebo Palate	M	14	0	0	0	0	0	0	0	0	0	2	3	6	1	2	0	0	0
		Ž	3	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	0	0	0	0	0	0	0	1	1	1	1	2	4	0	2	0	0
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	4	0	1	1	1
C07	Parotidna žleza Parotid gland	M	8	0	0	0	0	0	0	1	0	0	0	0	0	0	2	3	0	2
		Ž	6	0	1	0	0	0	0	0	1	0	0	0	1	0	0	1	1	1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C09	Tonzila Tonsil	M	43	0	0	0	0	0	0	0	0	2	2	5	8	9	5	8	3	1
		Ž	10	0	0	0	0	0	0	0	0	1	1	1	3	2	0	0	0	2
C10	Orofarinks Oropharynx	M	35	0	0	0	0	0	0	0	0	1	3	5	12	6	3	4	1	0
		Ž	6	0	0	0	0	0	0	0	0	1	1	0	0	1	1	2	0	0
C11	Nazofarinks Nasopharynx	M	8	0	0	0	0	0	0	0	1	0	1	2	0	0	3	0	1	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C12	Piriformni sinus Pyriiform sinus	M	41	0	0	0	0	0	0	0	1	0	1	5	9	7	8	5	3	2
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	24	0	0	0	0	0	0	0	0	0	1	1	3	8	6	3	0	2
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	70	0	0	0	0	0	0	0	0	0	0	5	11	15	12	10	7	8
		Ž	23	0	0	0	0	0	1	0	0	0	0	0	2	3	6	3	4	4
C16	Želodec Stomach	M	297	0	0	0	0	0	1	1	4	6	7	15	27	29	51	55	40	61
		Ž	159	0	0	0	0	0	0	2	1	2	2	9	13	15	13	25	24	53
C17	Tanko črevo Small intestine	M	18	0	0	0	0	0	0	0	0	0	2	2	1	1	1	4	5	2
		Ž	18	0	0	0	0	0	0	0	0	0	1	1	2	1	3	2	4	4
C18	Debelo črevo Colon	M	471	0	0	0	2	0	1	1	5	6	18	26	34	60	62	90	69	97
		Ž	382	0	0	0	0	0	1	1	4	5	6	21	27	35	42	69	48	123
C19	Rektosigmoidna zveza Rectosigmoid junction	M	65	0	0	0	0	0	0	0	0	0	3	7	4	7	5	16	16	7
		Ž	47	0	0	0	0	0	0	1	0	1	0	4	0	6	5	6	7	17
C20	Rektum Rectum	M	248	0	0	0	0	0	0	0	3	5	7	10	27	52	34	49	37	24
		Ž	140	0	0	0	0	0	0	1	0	1	4	9	8	14	17	25	21	40
C21	Anus in analni kanal Anus and anal canal	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0
		Ž	13	0	0	0	0	0	0	0	0	0	0	1	1	2	1	1	0	6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	163	0	0	0	1	1	0	0	0	2	1	5	21	33	32	28	17	22
		Ž	51	0	0	0	0	0	0	0	0	0	2	1	3	2	10	4	14	15
C23	Žolčnik Gallbladder	M	23	0	0	0	0	0	0	0	0	0	1	0	2	2	2	7	3	6
		Ž	37	0	0	0	0	0	0	0	0	0	0	2	1	5	4	10	5	10
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	0	0	0	0	0	0	0	0	0	1	2	2	5	5	13	10	16
		Ž	67	0	0	0	0	0	0	0	0	1	0	2	2	9	3	9	14	27
C25	Trebušna slinavka Pancreas	M	192	0	0	0	0	0	0	2	1	1	3	9	26	24	27	37	30	32
		Ž	199	0	0	0	0	0	0	1	1	1	3	6	8	24	19	31	41	64
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2

Nadaljevanje →
Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+		
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	7	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	2	2	0	
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	0	
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	1	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C32	Grlo Larynx	M	83	0	0	0	0	0	0	0	0	0	0	3	5	15	21	17	10	4	8	
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	3	
C33	Sapnik Trachea	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C34	Sapnica in pljuča Bronchus and lung	M	976	0	0	0	0	0	0	2	2	3	15	65	106	196	167	136	132	152		
		Ž	458	0	0	0	0	0	0	0	1	2	12	24	66	107	65	59	51	71		
C37	Timus Thymus	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	1	1	0	
		Ž	3	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	5	0	1	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	2	
		Ž	4	0	0	0	1	0	0	0	0	1	0	0	0	0	1	1	0	0	0	0
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	7	0	0	1	1	0	0	0	1	0	1	0	0	0	0	1	2	0	0	
		Ž	5	0	1	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	1
C43	Malignni melanom kože Malignant melanoma of skin	M	290	0	0	0	0	3	5	6	11	19	25	26	21	33	40	32	30	39		
		Ž	245	0	0	0	0	2	5	10	13	22	18	20	14	34	16	21	33	37		
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1397	0	0	0	0	2	6	9	18	18	41	83	97	152	209	197	236	329		
		Ž	1282	0	0	0	1	2	6	7	18	31	46	61	83	104	128	172	223	400		
C45	Mezoteliom Mesothelioma	M	30	0	0	0	0	0	0	0	0	1	2	0	1	3	3	7	8	5		
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	3	2	0	1	2	1		
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	3	0	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	
		Ž	3	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	0	0	0	
		Ž	17	0	0	0	0	0	0	0	0	0	0	1	0	2	5	2	3	4	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	31	0	0	1	1	0	2	1	0	3	0	1	1	4	2	3	7	5	0	
		Ž	25	1	0	0	2	1	1	1	0	0	1	3	2	3	1	0	4	5	0	0
C50	Dojka Breast	M	8	0	0	0	0	0	0	0	0	0	0	0	1	2	3	0	1	1	0	
		Ž	1319	0	0	0	0	1	9	22	40	68	124	147	150	200	165	111	124	158	0	0
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	58	0	0	0	0	0	0	0	0	0	3	4	4	3	4	8	12	20	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	10	0	0	0	0	0	0	0	0	0	2	0	0	1	1	1	1	4	0	0
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	119	0	0	0	0	0	3	6	12	13	15	12	12	21	2	5	7	11	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	355	0	0	0	0	0	1	1	2	8	12	42	42	53	53	54	35	52	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	16	0	0	0	0	0	0	0	0	1	3	1	1	2	1	1	1	5	0	0
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	151	0	0	0	0	1	1	2	3	7	14	21	21	24	13	7	12	25	0	0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	36	0	0	0	0	0	0	0	0	1	2	3	3	4	9	6	0	8	0	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	2	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	18	0	0	0	0	0	0	0	0	1	2	1	2	0	0	3	5	3	1	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1599	0	0	0	0	0	0	0	0	1	0	15	44	152	318	321	337	239	172	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	144	0	0	0	7	11	20	28	21	22	22	7	2	2	0	0	1	1
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	227	1	0	0	0	0	0	1	3	3	15	19	21	33	27	49	30	25
		Ž	105	2	0	0	0	0	0	0	2	0	4	7	9	16	15	17	16	17
C65	Ledvični meh Renal pelvis	M	14	0	0	0	0	0	0	0	0	0	0	1	0	3	1	2	2	5
		Ž	15	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	3	9
C66	Sečevod Ureter	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2
C67	Sečni mehur Bladder	M	249	0	0	0	0	0	0	0	0	5	3	6	21	29	27	40	50	68
		Ž	88	0	0	0	0	0	0	1	1	1	3	3	4	11	16	5	17	26
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	14	0	0	0	0	0	0	1	0	0	0	0	1	1	3	2	3	3
		Ž	15	3	0	0	0	0	1	0	1	1	1	1	2	0	1	2	1	1
C70	Meninge Meninges	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C71	Možgani Brain	M	98	1	0	0	2	5	1	6	2	4	9	11	15	14	13	8	7	7
		Ž	75	2	1	2	0	0	2	2	1	3	7	9	5	10	10	7	14	14
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0
C73	Ščitnica Thyroid gland	M	55	0	1	0	1	0	0	3	3	7	6	6	1	14	6	3	4	0
		Ž	150	0	0	1	2	3	4	16	8	13	14	14	11	13	19	14	10	8
C74	Nadledvična žleza Adrenal gland	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	8
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	19	0	0	0	0	0	0	0	0	0	0	3	3	6	3	1	1	2
		Ž	13	0	0	0	0	0	1	0	0	0	0	3	1	1	0	2	0	5
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	26	0	0	0	0	0	0	0	0	0	0	0	2	3	4	2	6	9
		Ž	53	0	0	0	0	0	0	0	0	0	0	2	2	2	1	4	8	34
C79	Metastaze, drugje Metastases of other sites	M	11	0	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	5
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	1	4	0	1	3	2
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	63	0	0	0	0	0	0	0	0	1	3	5	4	11	12	11	9	7
		Ž	63	0	0	0	0	0	0	0	1	1	2	2	4	6	3	9	13	22
C81	Hodgkinova bolezen Hodgkin's disease	M	29	1	1	0	3	3	5	1	1	1	1	2	1	4	1	1	3	0
		Ž	20	0	0	0	2	3	1	1	2	1	0	1	1	0	1	3	1	3
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	57	0	0	0	1	0	1	2	2	0	1	3	6	15	4	7	6	9
		Ž	60	0	0	0	0	0	0	1	1	1	3	6	8	8	11	7	4	10
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	138	0	1	0	0	1	1	3	2	2	6	7	11	13	16	24	28	23
		Ž	120	0	0	0	1	0	1	0	1	2	1	3	9	10	17	15	21	39
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	17	0	0	1	0	1	0	0	0	1	0	1	4	2	1	1	3	2
		Ž	16	0	0	0	0	0	0	0	0	1	2	0	1	3	2	1	3	3
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	4
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	7

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	0	0	0	0	0	0	0	1	0	1	3	8	4	5	7	10	7	13
		Ž	58	0	0	0	0	0	0	0	0	1	0	2	1	6	3	6	10	9	20
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	16	3	4	1	1	0	0	0	1	1	0	2	0	0	1	0	1	1	
		Ž	13	5	1	0	0	0	0	0	1	0	1	2	0	0	0	0	0	2	1
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	67	0	0	0	0	0	0	0	0	2	3	3	6	8	5	12	13	15	
		Ž	44	0	0	0	0	0	0	0	0	1	1	2	2	4	7	7	8	12	
C92	Mieloična levkemija Myeloid leukaemia	M	64	0	0	0	0	0	1	0	1	0	1	3	6	6	10	9	12	15	
		Ž	62	1	0	0	1	1	0	0	1	5	3	0	8	2	13	8	6	13	
C93	Monocitna levkemija Monocytic leukaemia	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
		Ž	5	1	0	0	0	0	0	0	1	0	0	0	0	0	1	1	1	0	0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	16	0	0	0	0	0	0	0	0	0	0	3	0	3	2	2	2	3	1
		Ž	16	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	5	3	4
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	88	0	1	0	0	0	1	0	3	1	0	4	6	10	2	14	19	27	
		Ž	94	0	0	0	0	1	2	1	1	0	2	3	4	6	8	10	13	43	

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
D03	Melanom, in situ Melanoma, in situ	M	96	0	0	0	0	2	0	3	4	7	2	11	13	9	10	12	10	13
		Ž	102	0	0	0	0	0	2	3	8	6	15	11	13	7	9	9	6	13
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	103	0	0	0	0	0	0	0	2	4	9	16	18	17	18	11	5	3
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ (CIN III)	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1154	0	0	0	4	91	176	253	213	151	103	59	36	35	17	10	5	1
D09.0	Sečni mehur, in situ Bladder, in situ	M	158	0	0	0	0	0	0	0	1	2	1	6	14	30	22	33	22	27
		Ž	47	0	0	0	0	0	0	0	0	1	0	3	7	7	7	3	6	13
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	28	0	0	1	0	0	0	1	0	1	0	2	1	4	4	6	4	4
		Ž	77	0	0	0	0	0	0	1	3	1	3	12	12	9	10	7	12	7
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behaviour	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	47	0	0	0	1	0	3	1	2	2	6	9	10	5	4	2	0	2
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	9	0	0	0	0	0	1	0	0	0	1	0	3	1	0	0	2	1
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	3

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2015.

Table 5: Crude and age specific cancer incidence rate per 100,000 and comulative rate (CR) by site and by sex, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00– C96	Vse lokacije All sites	M+Ž	694,6	22,1	13,3	8,8	31,7	38,6	66,9	98,3	137,2	217,0	368,8	584,2	859,5	1376,1	1754,8	2344,8	2622,4	2713,8	39,6
		M	768,6	10,8	18,5	8,5	38,8	47,8	72,5	82,9	113,8	157,8	312,8	559,5	961,1	1656,3	2275,0	3264,7	3626,9	4008,5	47,9
		Ž	621,8	34,2	7,8	9,0	24,0	28,9	60,9	115,1	163,0	281,5	427,4	609,5	755,7	1095,5	1277,8	1600,1	1913,4	2136,3	32,5
C00	Ustnica Lip	M	1,4	0	0	0	0	0	0	0	0	0	0	2,6	1,3	2,8	3,8	7,6	0	12,8	0,1
		Ž	1,3	0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	8,7	2,0	0	8,6	0,1
C01	Baza jezika Base of tongue	M	2,1	0	0	0	0	0	0	0	0	0	5,2	6,4	9,2	2,8	3,8	0	0	3,2	0,1
		Ž	0,7	0	0	0	0	0	0	0	0	2,8	0	1,3	2,7	0	1,7	2,0	0	0	0,1
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	2,8	0	0	0	0	0	0	0	0	3,9	3,9	5,1	5,3	4,2	9,5	10,1	9,6	0	0,2
		Ž	0,3	0	0	0	0	0	1,6	0	0	0	0	0	0	0	1,7	0	0	1,4	0,0
C03	Dlesen Gum	M	0,9	0	0	0	0	0	0	0	0	0	1,3	0	2,6	2,8	0	2,5	6,4	3,2	0,0
		Ž	0,5	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	2,0	2,3	2,9	0,0
C04	Ustno dno Floor of mouth	M	2,7	0	0	0	0	0	0	0	0	0	3,9	6,4	6,6	6,9	5,7	10,1	9,6	0	0,2
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,4	0	0	2,8	1,7	4,1	0	0	0,0
C05	Nebo Palate	M	1,4	0	0	0	0	0	0	0	0	0	2,6	3,8	7,9	1,4	3,8	0	0	0	0,1
		Ž	0,3	0	0	2,3	0	0	0	0	0	0	0	0	1,3	0	1,7	0	0	0	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	1,2	0	0	0	0	0	0	0	1,2	1,3	1,3	1,3	2,6	5,6	0	5,1	0	0	0,1
		Ž	0,7	0	0	0	0	0	0	0	0	0	0	0	0	5,6	0	2,0	2,3	1,4	0,0
C07	Parotidna žleza Parotid gland	M	0,8	0	0	0	0	0	0	1,3	0	0	0	0	0	0	3,8	7,6	0	6,4	0,1
		Ž	0,6	0	2,0	0	0	0	0	0	1,3	0	0	0	1,3	0	0	2,0	2,3	1,4	0,0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C09	Tonzila Tonsil	M	4,2	0	0	0	0	0	0	0	0	2,6	2,6	6,4	10,5	12,5	9,5	20,2	9,6	3,2	0,3
		Ž	1,0	0	0	0	0	0	0	0	0	1,4	1,4	1,3	4,0	2,8	0	0	0	2,9	0,1
C10	Orofarinks Oropharynx	M	3,4	0	0	0	0	0	0	0	0	1,3	3,9	6,4	15,8	8,3	5,7	10,1	3,2	0	0,3
		Ž	0,6	0	0	0	0	0	0	0	0	1,4	1,4	0	1,4	1,7	4,1	0	0	0	0,0
C11	Nazofarinks Nasopharynx	M	0,8	0	0	0	0	0	0	0	1,2	0	1,3	2,6	0	0	5,7	0	3,2	0	0,1
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0,0
C12	Piriformni sinus Pyriform sinus	M	4,0	0	0	0	0	0	0	0	1,2	0	1,3	6,4	11,9	9,7	15,2	12,7	9,6	6,4	0,3
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0,0
C13	Hipofarinks Hypopharynx	M	2,3	0	0	0	0	0	0	0	0	0	1,3	1,3	4,0	11,1	11,4	7,6	0	6,4	0,2
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	0	1,7	4,1	0	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	6,8	0	0	0	0	0	0	0	0	0	2,6	6,4	14,5	20,8	22,8	25,3	22,4	25,7	0,5
		Ž	2,2	0	0	0	0	0	1,6	0	0	0	0	0	2,7	4,2	10,5	6,1	9,0	5,7	0,1
C16	Želodec Stomach	M	29,0	0	0	0	0	0	1,5	1,3	4,8	7,8	9,0	19,2	35,6	40,3	97,1	139,2	128,2	195,9	1,8
		Ž	15,3	0	0	0	0	0	0	2,8	1,3	2,8	2,7	11,9	17,5	20,9	22,7	51,2	54,3	75,9	0,7
C17	Tanko črevo Small intestine	M	1,8	0	0	0	0	0	0	0	0	0	2,6	2,6	1,3	1,4	1,9	10,1	16,0	6,4	0,1
		Ž	1,7	0	0	0	0	0	0	0	0	0	1,4	1,3	2,7	1,4	5,2	4,1	9,0	5,7	0,1
C18	Debelo črevo Colon	M	46,1	0	0	0	4,1	0	1,5	1,3	6,1	7,8	23,3	33,4	44,8	83,3	118,0	227,8	221,1	311,6	2,8
		Ž	36,7	0	0	0	0	0	1,6	1,4	5,3	7,0	8,1	27,7	36,4	48,7	73,3	141,4	108,6	176,2	1,8

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	6,4	0	0	0	0	0	0	0	0	0	3,9	9,0	5,3	9,7	9,5	40,5	51,3	22,5	0,4
		Ž	4,5	0	0	0	0	0	0	1,4	0	1,4	0	5,3	0	8,3	8,7	12,3	15,8	24,4	0,2
C20	Rektum Rectum	M	24,3	0	0	0	0	0	0	0	3,6	6,5	9,0	12,8	35,6	72,2	64,7	124,0	118,5	77,1	1,6
		Ž	13,5	0	0	0	0	0	0	1,4	0	1,4	5,4	11,9	10,8	19,5	29,7	51,2	47,5	57,3	0,7
C21	Anus in analni kanal Anus and anal canal	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,4	3,8	0	0	0	0,0
		Ž	1,2	0	0	0	0	0	0	0	0	0	1,4	1,3	1,3	2,8	1,7	2,0	0	8,6	0,1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	15,9	0	0	0	2,0	1,8	0	0	0	2,6	1,3	6,4	27,7	45,8	60,9	70,9	54,5	70,7	1,1
		Ž	4,9	0	0	0	0	0	0	0	0	0	2,7	1,3	4,0	2,8	17,5	8,2	31,7	21,5	0,2
C23	Žolčnik Gallbladder	M	2,2	0	0	0	0	0	0	0	0	0	1,3	0	2,6	2,8	3,8	17,7	9,6	19,3	0,1
		Ž	3,6	0	0	0	0	0	0	0	0	0	0	2,6	1,3	7,0	7,0	20,5	11,3	14,3	0,2
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	5,3	0	0	0	0	0	0	0	0	0	1,3	2,6	2,6	6,9	9,5	32,9	32,0	51,4	0,3
		Ž	6,4	0	0	0	0	0	0	0	0	1,4	0	2,6	2,7	12,5	5,2	18,4	31,7	38,7	0,2
C25	Trebušna slinavka Pancreas	M	18,8	0	0	0	0	0	0	2,6	1,2	1,3	3,9	11,5	34,3	33,3	51,4	93,6	96,1	102,8	1,2
		Ž	19,1	0	0	0	0	0	0	1,4	1,3	1,4	4,1	7,9	10,8	33,4	33,2	63,5	92,7	91,7	0,8
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	0	1,9	2,5	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,9	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,7	0	0	0	0	0	0	0	0	0	0	0	2,6	1,4	0	5,1	6,4	0	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	1,4	1,7	2,0	0	0	0,0
C31	Obnosni sinusi Accessory sinuses	M	0,4	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	1,9	0	0	3,2	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,3	1,4	0,0
C32	Grlo Larynx	M	8,1	0	0	0	0	0	0	0	0	0	3,9	6,4	19,8	29,2	32,4	25,3	12,8	25,7	0,6
		Ž	0,7	0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	0	2,0	0	4,3	0,0
C33	Sapnik Trachea	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	2,5	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,9	0,0
C34	Sapnica in pljuča Bronchus and lung	M	95,4	0	0	0	0	0	0	2,6	2,4	3,9	19,4	83,4	139,7	272,1	317,9	344,2	422,9	488,2	5,9
		Ž	44,0	0	0	0	0	0	0	0	1,3	2,8	16,2	31,7	88,9	148,8	113,5	120,9	115,3	101,7	2,6
C37	Timus Thymus	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,5	3,2	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	1,4	0	1,3	0	0	0	0	0	0	0,0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,4	0	0	0	0	1,8	0	0	1,2	0	0	0	0	0	0	2,5	3,2	0	0,0
		Ž	0,3	3,8	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,5	0	1,8	0	2,0	0	0	0	0	0	0	0	0	1,4	0	0	0	6,4	0,0
		Ž	0,4	0	0	2,2	0	0	0	0	0	1,4	0	0	0	1,4	1,7	0	0	0	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,7	0	0	2,1	2,0	0	0	0	1,2	0	1,3	0	0	0	0	2,5	6,4	0	0,0
		Ž	0,5	0	2,0	0	2,2	0	0	0	1,3	0	0	1,3	0	0	0	0	0	1,4	0,0
C43	Malignni melanom kože Malignant melanoma of skin	M	28,4	0	0	0	0	5,5	7,4	7,8	13,3	24,6	32,3	33,4	27,7	45,8	76,2	81,0	96,1	125,3	1,8
		Ž	23,5	0	0	0	0	3,9	8,0	14,2	17,4	31,0	24,3	26,4	18,9	47,3	27,9	43,0	74,6	53,0	1,3
C44	Druge maligne neoplazme kože Skin, other malignomas	M	136,6	0	0	0	0	3,7	8,9	11,7	21,8	23,3	53,0	106,5	127,9	211,0	397,9	498,6	756,1	1056,7	7,3
		Ž	123,2	0	0	0	2,2	3,9	9,6	9,9	24,0	43,6	62,2	80,5	111,8	144,6	223,4	352,4	504,4	573,1	5,3
C45	Mezoteliom Mesothelioma	M	2,9	0	0	0	0	0	0	0	0	1,3	2,6	0	1,3	4,2	5,7	17,7	25,6	16,1	0,2
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	0	4,0	2,8	0	2,0	4,5	1,4	0,0
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0,3	0	1,8	0	0	0	0	0	0	0	0	0	1,3	0	1,9	0	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	1,4	0	1,4	0	0	1,3	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,5	0	0	0	0	0	0	0	0	0	0	1,3	2,6	2,8	0	0	0	0	0,0
		Ž	1,6	0	0	0	0	0	0	0	0	0	0	1,3	0	2,8	8,7	4,1	6,8	5,7	0,1
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	3,0	0	0	2,1	2,0	0	3,0	1,3	0	3,9	0	1,3	1,3	5,6	3,8	7,6	22,4	16,1	0,2
		Ž	2,4	1,9	0	0	4,4	1,9	1,6	1,4	0	0	1,4	4,0	2,7	4,2	1,7	0	9,0	7,2	0,1
C50	Dojka Breast	M	0,8	0	0	0	0	0	0	0	0	0	0	0	1,3	2,8	5,7	0	3,2	3,2	0,0
		Ž	126,8	0	0	0	0	1,9	14,4	31,3	53,4	95,7	167,7	193,9	202,1	278,1	288,0	227,4	280,4	226,4	7,8
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	5,6	0	0	0	0	0	0	0	0	0	4,1	5,3	5,4	4,2	7,0	16,4	27,1	28,7	0,2
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1,0	0	0	0	0	0	0	0	0	0	2,7	0	0	1,4	1,7	2,0	2,3	5,7	0,0
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	11,4	0	0	0	0	0	4,8	8,5	16,0	18,3	20,3	15,8	16,2	29,2	3,5	10,2	15,8	15,8	0,7
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	34,1	0	0	0	0	0	1,6	1,4	2,7	11,3	16,2	55,4	56,6	73,7	92,5	110,6	79,2	74,5	2,1
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	1,5	0	0	0	0	0	0	0	0	1,4	4,1	1,3	1,3	2,8	1,7	2,0	2,3	7,2	0,1
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	14,5	0	0	0	0	1,9	1,6	2,8	4,0	9,9	18,9	27,7	28,3	33,4	22,7	14,3	27,1	35,8	0,8
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	3,5	0	0	0	0	0	0	0	0	1,4	2,7	4,0	4,0	5,6	15,7	12,3	0	11,5	0,2
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	0,2	0	0	0	0	0	0	1,4	0	1,4	0	0	0	0	0	0	0	0	0,0
C60	Penis Penis	M	1,8	0	0	0	0	0	0	0	1,2	2,6	1,3	2,6	0	0	5,7	12,7	9,6	3,2	0,1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C61	Prostata Prostate	M	156,4	0	0	0	0	0	0	0	1,2	0	19,4	56,5	200,4	441,5	611,1	852,9	765,8	552,5	10,9
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	14,1	0	0	0	14,3	20,2	29,6	36,3	25,4	28,4	28,4	9,0	2,6	2,8	0	0	3,2	3,2	1,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	0	0,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	22,2	1,8	0	0	0	0	0	1,3	3,6	3,9	19,4	24,4	27,7	45,8	51,4	124,0	96,1	80,3	1,5
		Ž	10,1	3,8	0	0	0	0	0	0	2,7	0	5,4	9,2	12,1	22,2	26,2	34,8	36,2	24,4	0,6
C65	Ledvični meh Renal pelvis	M	1,4	0	0	0	0	0	0	0	0	0	0	1,3	0	4,2	1,9	5,1	6,4	16,1	0,1
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	0	0	2,8	1,7	0	6,8	12,9	0,0
C66	Sečevod Ureter	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	3,2	0,0
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,3	2,9	0,0
C67	Sečni mehur Bladder	M	24,4	0	0	0	0	0	0	0	0	6,5	3,9	7,7	27,7	40,3	51,4	101,2	160,2	218,4	1,2
		Ž	8,5	0	0	0	0	0	0	1,4	1,3	1,4	4,1	4,0	5,4	15,3	27,9	10,2	38,4	37,3	0,4
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	3,2	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C69	Oko in očesni adneksi Eye and adnexa	M	1,4	0	0	0	0	0	0	1,3	0	0	0	0	1,3	1,4	5,7	5,1	9,6	9,6	0,1
		Ž	1,4	5,7	0	0	0	0	1,6	0	1,3	1,4	1,4	1,3	2,7	0	1,7	4,1	2,3	1,4	0,1
C70	Meninge Meninges	M	0,3	0	0	0	0	0	0	0	0	0	0	0	1,3	0	1,9	2,5	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C71	Možgani Brain	M	9,6	1,8	0	0	0	3,7	7,4	1,3	7,3	2,6	5,2	11,5	14,5	20,8	26,7	32,9	25,6	22,5	0,7
		Ž	7,2	3,8	2,0	4,5	0	0	0	2,8	2,7	1,4	4,1	9,2	12,1	7,0	17,5	20,5	15,8	20,1	0,4
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	2,0	0	0	0,0
C73	Ščitnica Thyroid gland	M	5,4	0	1,8	0	2,0	0	0	3,9	3,6	9,1	7,8	7,7	1,3	19,4	11,4	7,6	12,8	0	0,4
		Ž	14,4	0	0	2,3	4,4	5,8	6,4	22,7	10,7	18,3	18,9	18,5	14,8	18,1	33,2	28,7	22,6	11,5	1,0
C74	Nadledvična žleza Adrenal gland	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,1	1,9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0,1	0	0	0	0	1,8	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,4	0	0	0	0	0	0	0	0	0	0	0	0	0	3,8	2,5	0	3,2	0,0
		Ž	1,1	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0	2,0	2,3	11,5	0,0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	1,9	0	0	0	0	0	0	0	0	0	0	3,8	4,0	8,3	5,7	2,5	3,2	6,4	0,1
		Ž	1,2	0	0	0	0	0	0	1,4	0	0	0	0	4,0	1,3	1,4	0	4,1	0	7,2

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C78	Metastaze dihal in prebavil	M	2,5	0	0	0	0	0	0	0	0	0	0	0	2,6	4,2	7,6	5,1	19,2	28,9	0,1
	Metastases of respiratory and digestive organs	Ž	5,1	0	0	0	0	0	0	0	0	0	0	2,6	2,7	2,8	1,7	8,2	18,1	48,7	0,1
C79	Metastaze, drugje	M	1,1	0	0	0	0	0	0	0	0	0	0	0	0	0	1,9	10,1	3,2	16,1	0,1
	Metastases of other sites	Ž	1,1	0	0	0	0	0	0	0	0	0	0	1,3	5,6	0	2,0	6,8	2,9	0,0	0,0
C80	Maligna neoplazma brez opredeljenega mesta	M	6,2	0	0	0	0	0	0	0	1,3	3,9	6,4	5,3	15,3	22,8	27,8	28,8	22,5	0,4	
	Malignant neoplasm without specification of site	Ž	6,1	0	0	0	0	0	0	1,3	1,4	2,7	2,6	5,4	8,3	5,2	18,4	29,4	31,5	0,2	
C81	Hodgkinova bolezen	M	2,8	1,8	1,8	0	6,1	5,5	7,4	1,3	1,2	1,3	1,3	2,6	1,3	5,6	1,9	2,5	9,6	0	0,2
	Hodgkin's disease	Ž	1,9	0	0	0	4,4	5,8	1,6	1,4	2,7	1,4	0	1,3	1,3	0	1,7	6,1	2,3	4,3	0,1
C82	Folikularni ne-Hodgkinov limfom	M	5,6	0	0	0	2,0	0	1,5	2,6	2,4	0	1,3	3,8	7,9	20,8	7,6	17,7	19,2	28,9	0,3
	Follicular non-Hodgkin's lymphoma	Ž	5,8	0	0	0	0	0	0	1,4	1,3	1,4	4,1	7,9	10,8	11,1	19,2	14,3	9,0	14,3	0,4
C83	Difuzni ne-Hodgkinov limfom	M	13,5	0	1,8	0	0	1,8	1,5	3,9	2,4	2,6	7,8	9,0	14,5	18,0	30,5	60,7	89,7	73,9	0,8
	Diffuse non-Hodgkin's lymphoma	Ž	11,5	0	0	0	2,2	0	1,6	0	1,3	2,8	1,4	4,0	12,1	13,9	29,7	30,7	47,5	55,9	0,5
C84	Limfomi celic T in kožni limfom celic T	M	1,7	0	0	2,1	0	1,8	0	0	0	1,3	0	1,3	5,3	2,8	1,9	2,5	9,6	6,4	0,1
	Peripheral and cutaneous T-cell lymphomas	Ž	1,5	0	0	0	0	0	0	0	0	1,4	2,7	0	1,3	4,2	3,5	2,0	6,8	4,3	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	0,5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	12,8	0,0
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	4,5	10,0	0,0
C88	Maligne imunoproliferativne bolezni	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Malignant immunoproliferative diseases	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	5,8	0	0	0	0	0	0	1,3	0	1,3	3,9	10,3	5,3	6,9	13,3	25,3	22,4	41,8	0,3
	Multiple myeloma and malignant plasma cell neoplasms	Ž	5,6	0	0	0	0	0	0	0	1,3	0	2,7	1,3	8,1	4,2	10,5	20,5	20,4	28,7	0,2
C91.0	Limfatična levkemija, akutna	M	1,6	5,4	7,4	2,1	2,0	0	0	0	1,2	1,3	0	2,6	0	0	1,9	0	3,2	3,2	0,1
	Lymphoblastic leukaemia, acute	Ž	1,2	9,5	2,0	0	0	0	0	0	1,3	0	1,4	2,6	0	0	0	0	4,5	1,4	0,1
C91.1 C91.9	Limfatična levkemija, druga	M	6,6	0	0	0	0	0	0	0	0	2,6	3,9	3,8	7,9	11,1	9,5	30,4	41,7	48,2	0,3
	Lymphoid leukaemia, other	Ž	4,2	0	0	0	0	0	0	0	0	1,4	1,4	2,6	2,7	5,6	12,2	14,3	18,1	17,2	0,2
C92	Mieloična levkemija	M	6,3	0	0	0	0	1,5	0	1,2	0	1,3	3,8	7,9	8,3	19,0	22,8	38,4	48,2	0,3	
	Myeloid leukaemia	Ž	6,0	1,9	0	0	2,2	1,9	0	0	1,3	7,0	4,1	0	10,8	2,8	22,7	16,4	13,6	18,6	0,4
C93	Monocitna levkemija	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	3,2	0,0
	Monocytic leukaemia	Ž	0,5	1,9	0	0	0	0	0	1,4	0	0	0	0	0	1,4	1,7	2,0	0	0	0,0

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C94	Druge opredeljene levkemije	M	1,6	0	0	0	0	0	0	0	0	0	3,9	0	4,0	2,8	3,8	5,1	9,6	3,2	0,1
	Other leukaemias of specified cells	Ž	1,5	0	0	0	0	0	0	0	0	0	0	1,3	0	2,8	1,7	10,2	6,8	5,7	0,1
C95	Levkemija z neopredeljenim celičnim tipom	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,5	6,4	0	0,0
	Leukaemia, unspecified cell type	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,4	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	8,6	0	1,8	0	0	0	1,5	0	3,6	1,3	0	5,1	7,9	13,9	3,8	35,4	60,9	86,7	0,4
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	9,0	0	0	0	0	1,9	3,2	1,4	1,3	0	2,7	4,0	5,4	8,3	14,0	20,5	29,4	61,6	0,3

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ	M	9,4	0	0	0	0	3,7	0	3,9	4,8	9,1	2,6	14,1	17,1	12,5	19,0	30,4	32,0	41,8	0,6
	Melanoma, in situ	Ž	9,8	0	0	0	0	3,2	4,3	10,7	8,4	20,3	14,5	17,5	9,7	15,7	18,4	13,6	18,6	0,6	
D05	Dojka, in situ	M	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Breast, in situ	Ž	9,9	0	0	0	0	0	0	2,7	5,6	12,2	21,1	24,2	23,6	31,4	22,5	11,3	4,3	0,7	
D06	Maternični vrat, in situ (CIN III)	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri, in situ (CIN III)	Ž	110,9	0	0	0	8,7	175,6	282,0	359,4	284,5	212,5	139,3	77,8	48,5	48,7	29,7	20,5	11,3	1,4	8,4
D09.0	Sečni mehur, in situ	M	15,5	0	0	0	0	0	0	1,2	2,6	1,3	7,7	18,5	41,7	41,9	83,5	70,5	86,7	1,0	
	Bladder, in situ	Ž	4,5	0	0	0	0	0	0	0	1,4	0	4,0	9,4	9,7	12,2	6,1	13,6	18,6	0,2	
D32.0, D42.0	Meninge, benigna neoplazma in neoplazma negotovega značaja	M	2,7	0	0	2,1	0	0	0	1,3	0	1,3	0	2,6	1,3	5,6	7,6	15,2	12,8	12,8	0,2
	Benign neoplasm and neoplasm of uncertain behaviour of meninges	Ž	7,4	0	0	0	0	0	0	1,4	4,0	1,4	4,1	15,8	16,2	12,5	17,5	14,3	27,1	10,0	0,4
D33.0 D33.2	Možgani, benigna neoplazma	M	0,1	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0,0
	Benign neoplasm of brain	Ž	0,0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary, neopl. of uncertain behavior	Ž	4,5	0	0	0	2,2	0	4,8	1,4	2,7	2,8	8,1	11,9	13,5	7,0	7,0	4,1	0	2,9	0,3
D43.0 D43.2	Možgani, neopredeljeno	M	0,9	0	0	0	0	0	1,5	0	0	0	1,3	0	4,0	1,4	0	0	6,4	3,2	0,0
	CNS, uncertain or unknown	Ž	0,7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	6,8	4,3	0,0

Tabela 6a: Incidenca po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2015.

Table 6a: Incidence by statistical regions, by sex and by selected primary cancer site, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenija, total	Statistična regija / Statistical region											
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Posavska	Jugovzhodna Slovenija	Osvrednjelovska	Gorenjska	Primorsko- notranjska	Goriška	Obalno-kraška
C00–C96	Vse lokacije All sites	M+Ž	14329	967	2035	513	1574	304	455	972	4023	1499	333	917	737
		M	7859	554	1128	310	844	158	247	529	2150	833	183	518	405
		Ž	6470	413	907	203	730	146	208	443	1873	666	150	399	332
		M	286	28	57	12	36	7	14	23	54	19	8	13	15
C00–C14	Usta in žrelo Mouth and pharynx	Ž	73	5	16	2	7	0	4	0	24	7	2	3	3
		M	70	2	8	2	9	1	1	8	21	7	2	5	4
C15	Požiralnik Oesophagus	Ž	23	0	3	0	3	2	1	3	3	5	1	2	0
		M	297	25	62	17	34	4	8	20	65	25	4	18	15
C16	Želodec Stomach	Ž	159	6	36	6	17	2	3	10	41	10	4	13	11
		M	471	29	76	20	45	21	18	24	124	43	13	42	16
C18	Debelo črevo Colon	Ž	382	16	58	9	46	5	10	26	109	40	15	33	15
		M	313	24	52	15	34	7	19	22	75	29	4	16	16
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	187	19	32	6	23	7	6	16	39	13	4	13	9
		M	163	6	32	7	20	3	4	14	41	12	4	9	11
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	51	3	4	2	7	1	1	5	12	7	0	4	5
		M	77	3	17	3	8	2	1	2	28	9	2	1	1
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	104	4	22	3	13	2	3	8	23	13	3	4	6
		M	192	7	27	5	17	4	7	16	53	20	7	14	15
C25	Trebušna slinavka Pancreas	Ž	199	11	22	9	24	3	4	13	59	16	7	15	16
		M	83	7	12	5	11	2	4	5	11	11	4	6	5
C32	Grlo Larynx	Ž	7	2	1	0	0	0	0	0	3	1	0	0	0
		M	978	62	159	47	101	22	25	57	264	113	26	47	55
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	460	25	59	16	44	17	12	31	146	45	10	28	27
		M	290	14	34	2	37	5	11	15	100	38	3	16	15
C43	Maligni melanom kože Malignant melanoma of skin	Ž	245	13	29	8	31	5	11	20	62	36	4	11	15
		M	1397	102	133	74	174	11	31	112	447	159	19	88	47
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	1282	117	124	45	163	13	34	97	432	138	15	58	46
		M	36	1	2	2	4	0	0	8	14	1	2	1	1
C48–C49	Veživo in mehko tkivo Connective and soft tissue	Ž	42	4	8	1	8	0	0	0	9	3	1	6	2
		M	8	0	4	0	1	0	1	0	0	1	0	1	0
C50	Dojka Breast	Ž	1319	70	211	35	144	34	48	96	341	145	28	86	81
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C53	Maternični vrat Cervix uteri	Ž	119	7	20	5	15	5	4	10	35	3	7	4	4
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C54	Maternično telo Corpus uteri	Ž	355	28	57	12	37	11	12	24	95	34	12	18	15
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C56	Jajčnik Ovary	Ž	151	7	35	3	23	2	3	6	32	16	5	9	10
		M	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
		M	1599	160	214	59	136	30	55	91	396	173	45	131	109
C62	Modo Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–
		M	144	7	23	1	24	3	3	6	38	13	4	10	12
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	Ž	120	16	17	5	8	2	3	10	36	14	1	4	4
		M	241	24	45	6	25	4	12	16	55	23	3	18	10
C67	Sečni mehur Bladder	Ž	88	4	16	5	5	2	4	5	29	5	1	7	5
		M	249	11	46	11	16	8	5	16	78	29	7	9	13
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	77	0	16	6	8	2	3	6	16	10	5	3	2
		M	102	5	16	1	8	4	4	6	30	14	2	7	5
C73	Ščitnica Thyroid gland	Ž	150	5	9	3	29	4	7	12	43	13	4	14	7
		M	55	3	10	1	10	0	4	7	8	4	3	3	2
C81	Hodgkinova bolezen Hodgkin's disease	Ž	20	1	1	1	1	0	2	0	7	2	1	2	2
		M	29	0	4	2	8	1	1	3	6	2	0	2	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	206	13	24	4	22	9	5	15	65	18	5	13	13
		M	217	9	30	7	23	3	9	21	66	16	6	15	12
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	58	5	9	2	4	1	3	3	17	6	0	5	3
		M	59	2	8	2	6	0	1	2	17	10	1	4	6
C91–C95	Levkemije Leukaemias	Ž	141	7	23	2	8	5	2	8	57	12	4	9	4
		M	168	6	16	2	18	4	2	14	60	21	6	9	10

Tabela 6b: Starostno standardizirana* incidenčna stopnja po statističnih regijah, spolu in izbrani primarni lokaciji raka, Slovenija 2015.

Table 6b: Age standardised* incidence rate by statistical regions, by sex and by selected primary cancer site, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Slovenija, skupaj Slovenija, total	Statistična regija / Statistical region												
				Pomurska	Podravska	Koroška	Savinjska	Zasavska	Posavska	Jugovzhodna Slovenija	Osprednjeslovenska	Gorenjska	Primorsko-notranjska	Goriška	Obalno-krška	
C00–C96	Vse lokacije All sites	M+Ž	569,2	633,2	502,9	576,2	521,5	420,6	479,0	580,0	648,1	601,9	506,2	585,1	520,0	
		M	704,5	836,1	629,0	765,5	618,5	488,6	583,1	704,9	795,8	760,4	600,9	732,9	632,0	
C00–C14	Usta in žrelo Mouth and pharynx	Ž	471,7	487,7	410,8	426,0	457,4	380,4	406,7	490,9	543,5	480,6	434,2	475,0	444,8	
		M	24,9	38,1	31,3	32,9	24,1	21,1	31,8	28,3	19,5	18,0	23,2	17,4	24,2	
C15	Požiralnik Esophagus	Ž	5,6	5,5	8,3	3,2	4,0	0,0	7,3	0,0	7,6	5,6	4,6	4,1	5,2	
		M	6,0	2,8	4,0	4,3	5,9	3,3	3,0	10,3	8,2	6,0	6,2	7,1	4,8	
C16	Želodec Stomach	Ž	1,7	0,0	1,3	0,0	1,6	5,8	2,4	3,8	0,9	3,5	2,8	2,5	0,0	
		M	26,8	40,0	35,3	43,1	24,7	13,9	17,9	27,1	24,2	22,6	12,0	24,7	21,9	
C18	Debelo črevo Colon	Ž	10,5	6,4	15,3	11,8	8,8	5,4	6,1	8,7	11,1	7,1	9,2	12,0	13,8	
		M	42,6	46,3	42,1	50,7	32,1	68,4	41,7	32,5	46,1	40,3	44,3	58,0	27,5	
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	25,7	17,4	23,5	18,5	25,8	10,8	20,2	25,9	29,5	27,0	39,5	39,3	17,2	
		M	28,1	34,7	28,8	36,8	25,2	19,6	43,1	29,3	28,2	27,5	11,5	24,1	25,0	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	12,7	18,5	13,6	11,8	13,8	17,3	9,9	14,3	12,1	7,4	11,6	14,1	10,0	
		M	14,3	9,4	18,0	15,1	14,2	8,9	8,3	19,2	14,8	10,5	11,8	13,0	15,6	
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	3,4	3,3	1,6	4,6	4,7	2,5	0,9	5,7	2,3	5,0	0,0	4,1	6,4	
		M	7,0	4,2	9,7	6,8	6,1	5,7	3,0	2,7	10,7	7,9	6,5	1,1	2,0	
C25	Trebušna slinavka Pancreas	Ž	6,6	4,6	8,6	5,2	7,3	3,7	5,4	8,4	5,9	8,4	7,8	4,5	5,0	
		M	17,1	10,4	15,3	10,2	12,1	11,8	18,6	21,1	19,3	18,9	21,8	19,3	23,7	
C32	Grlo Larynx	Ž	13,0	14,4	8,8	18,4	13,1	6,4	7,6	12,2	15,5	9,9	15,8	15,5	18,7	
		M	7,0	10,1	5,7	11,9	7,8	5,9	7,3	7,4	3,8	9,2	12,3	8,4	8,4	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	0,4	1,8	0,5	0,0	0,0	0,0	0,0	0,0	0,7	1,0	0,0	0,0	0,0	
		M	85,4	91,2	85,9	113,3	73,0	64,4	56,6	76,1	96,7	99,8	82,5	62,5	81,3	
C43	Maligni melanom kože Malignant melanoma of skin	Ž	33,2	29,5	27,1	31,9	25,8	43,5	23,9	33,9	43,2	32,8	25,8	30,5	34,3	
		M	26,6	22,4	19,3	5,7	26,5	14,0	26,4	20,2	37,5	36,7	10,3	22,5	24,4	
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	19,8	18,1	14,8	20,4	20,7	17,8	23,6	23,1	20,0	28,0	11,3	15,1	22,5	
		M	125,5	152,4	75,6	185,2	130,5	35,3	76,5	147,5	163,9	143,3	63,4	124,8	71,2	
C48–C49	Veživo in mehko tkivo Connective and soft tissue	Ž	87,2	127,3	50,0	88,8	97,4	32,5	66,0	100,8	117,3	93,7	40,8	64,0	58,5	
		M	3,3	1,1	1,2	4,6	3,0	0,0	0,0	11,0	5,4	0,9	6,5	1,1	1,2	
C50	Dojka Breast	Ž	3,2	4,3	3,9	2,6	6,1	0,0	0,0	0,0	3,0	1,8	1,3	6,5	2,8	
		M	0,7	0,0	2,2	0,0	0,7	0,0	1,8	0,0	0,0	0,8	0,0	1,4	0,0	
C53	Maternični vrat Cervix uteri	Ž	105,7	93,8	106,4	74,5	98,6	92,4	91,7	115,9	110,3	115,2	91,0	108,5	121,1	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C54	Maternično telo Corpus uteri	Ž	10,3	10,5	10,1	12,7	11,1	14,1	9,8	12,3	11,7	2,1	27,2	7,4	6,6	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C56	Jajčnik Ovary	Ž	26,9	32,8	25,9	27,6	24,6	31,7	26,1	29,7	29,4	23,5	38,1	20,2	19,7	
		M	–	–	–	–	–	–	–	–	–	–	–	–	–	
C61	Prostata Prostate	Ž	11,8	9,1	17,9	6,3	15,8	4,3	5,6	8,0	9,9	10,6	15,9	13,1	10,6	
		M	142,3	239,2	116,1	144,3	98,7	87,7	130,0	120,0	148,5	157,6	151,2	181,8	169,2	
C62	Modo Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	
		M	14,9	12,9	15,4	2,5	20,1	12,3	7,3	8,1	14,8	13,6	15,6	20,0	22,9	
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	
		M	21,9	35,2	25,0	15,9	18,0	13,5	28,9	21,1	20,6	20,3	11,7	25,7	16,7	
C67	Sečni mehur Bladder	Ž	8,5	23,2	7,3	9,0	4,8	5,0	4,8	8,7	10,6	9,9	3,6	3,9	4,8	
		M	22,2	19,6	25,9	26,8	12,0	25,6	12,4	21,8	28,6	26,7	22,2	12,5	19,6	
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	5,9	4,5	6,8	9,8	2,0	5,2	7,8	5,8	7,3	4,4	3,6	7,8	6,1	
		M	9,3	8,2	9,2	1,7	5,7	12,4	9,7	8,2	11,2	13,4	6,9	9,9	8,3	
C73	Ščitnica Thyroid gland	Ž	5,9	0,0	8,1	12,6	5,9	2,5	6,5	6,8	4,9	8,2	17,2	2,6	1,8	
		M	5,0	5,2	5,7	1,9	7,3	0,0	9,5	9,6	3,0	3,4	11,7	3,8	2,9	
C81	Hodgkinova bolezen Hodgkin's disease	Ž	13,6	6,0	5,0	7,5	22,5	11,5	17,8	17,9	14,9	11,7	12,9	22,0	11,9	
		M	3,0	0,0	2,5	5,1	6,4	5,4	2,6	4,7	2,3	2,4	0,0	4,5	0,0	
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	2,0	2,6	0,7	3,9	0,7	0,0	6,2	0,0	2,3	1,8	1,3	7,2	3,2	
		M	19,6	12,8	17,4	19,7	17,0	8,3	22,0	28,7	24,2	14,4	19,8	20,5	19,1	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	14,2	14,2	9,9	10,4	13,6	20,6	7,8	15,3	16,8	14,0	15,0	14,5	16,5	
		M	5,4	2,7	4,6	4,8	4,6	0,0	3,0	2,4	6,2	9,2	4,2	5,6	8,5	
C91–C95	Levkemije Leukaemias	Ž	3,8	5,8	3,1	4,5	1,7	3,0	6,2	3,5	4,1	4,4	0,0	6,6	3,5	
		M	15,2	9,6	9,2	4,7	13,9	12,6	4,6	18,8	22,2	18,3	18,7	14,0	17,7	
		Ž	10,5	9,6	10,9	3,7	5,0	16,3	2,8	9,8	16,5	9,3	9,4	6,8		

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2015.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2015.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	25	3	28	0	32	0	14	0	34	0	16	1	19	0	13	1	0	0	52	1		
Small cell carcinoma	203	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	25	3	27	0	32	0	13	0	34	0	14	0	18	0	3	0	0	0	52	1		
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	0	0	1	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0
Other specified carcinomas	106	8	0	0	0	0	0	0	1	0	0	0	1	1	0	0	4	0	0	0	0	0	0	0
Carcinoma, unspecified	75	124	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	41	0	9	0	42	0	28	0	0	0	86	2	442	4	33	2	805	5	111	0		
Small cell carcinoma	203	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	41	0	9	0	41	0	28	0	0	0	66	1	2	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	0	0	0	0	0	0	0	0	0	0	15	0	408	2	20	1	792	3	111	0		
Other specified carcinomas	106	8	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0
Carcinoma, unspecified	75	124	0	0	0	0	1	0	0	0	0	0	4	1	6	2	0	0	9	1	0	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	0	0	0	0	0	0	1	0	24	0	12	1	2	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C06		C20		C21		C22		C23		C24		C25		C26		C30		C31	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	377	1	16	0	107	27	37	6	63	11	199	54	2	0	11	0	6	0	89	1
Small cell carcinoma	203	50	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	1	0	13	0	0	0	0	1	0	0	0	0	0	0	5	0	3	0	87	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	370	0	2	0	106	27	34	5	62	8	184	37	2	0	3	0	2	0	0	0
Other specified carcinomas	106	8	0	0	0	0	0	0	2	0	0	0	8	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	75	124	4	1	0	0	0	0	1	1	0	2	7	16	0	0	0	0	0	0	2	1
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C06		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	4	0	1121	204	4	0	6	1	0	0	9	0	11	0	532	3	2625	51	35	4		
Small cell carcinoma	203	50	0	0	191	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	83	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	2	0	332	26	0	0	0	0	0	0	0	0	0	0	0	0	0	431	20	0	0	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2165	26	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	1	0	465	85	0	0	0	0	0	0	0	0	0	0	0	0	0	18	1	0	0	0
Other specified carcinomas	106	8	1	0	39	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0
Carcinoma, unspecified	75	124	0	0	9	15	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0
Malignant thymoma	4	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	532	3	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	4	0	3	0	0	0	0	1	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	4	0	3	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	1	0	3	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	35	4	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	0	0	6	0	21	0	55	1	1219	98	58	0	10	0	119	0	354	0	14	0
Small cell carcinoma	203	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	0	0	0	0	0	0	0	0	0	0	47	0	4	0	82	0	0	0	1	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	9	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	0	0	0	0	9	0	0	0	1199	35	2	0	3	0	30	0	319	0	0	0
Other specified carcinomas	106	8	0	0	0	0	0	0	0	0	9	0	0	0	0	0	4	0	19	0	0	0
Carcinoma, unspecified	75	124	0	0	0	0	0	0	0	0	7	63	0	0	1	0	1	0	2	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	5	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	2	0	4	0	0	0	0	0	0	0	2	0	0	0	7	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	8	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	2	0	18	1	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	2	0	2	0	0	0	0	0	1	0	0	0	14	0	6	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																						
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66		
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	
Vse vrste/All types	12975	644	134	8	33	1	2	0	18	0	1542	4	143	0	1	0	291	7	25	2	5	1			
Small cell carcinoma	203	50	1	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	0		
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	1	0	0	0	0	0	18	0	0	0	0	0	0	0	0	0	0	1	1	0	0		
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	24	0	4	1		
Adenocarcinoma	6411	241	119	5	31	1	0	0	0	0	1533	3	0	0	0	0	286	5	0	0	0	0	0	0	0
Other specified carcinomas	106	8	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Carcinoma, unspecified	75	124	0	2	1	0	0	0	0	0	3	1	0	0	0	0	0	2	0	0	0	0	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	4	0	1	0	0	0	0	0	1	0	0	0	0	0	3	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	87	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	1	0	0	0	0	0	0	0	0	0	51	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	2	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	323	8	1	0	27	0	3	0	148	0	3	0	194	11	1	0	1	0	4	1
Small cell carcinoma	203	50	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	311	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	2	0	0	0	0	0	0	0	0	0	0	0	188	6	0	0	0	0	1	1
Other specified carcinomas	106	8	1	0	0	0	0	0	0	0	0	0	0	0	4	3	0	0	0	0	0	0
Carcinoma, unspecified	75	124	2	5	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	147	0	3	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	22	9	39	11	11	2	69	14	47	2	112	5	240	18	31	2	12	3	0	0		
Small cell carcinoma	203	50	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	11	4	1	0	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	6	1	27	8	5	1	50	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified carcinomas	106	8	0	1	2	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	75	124	1	1	5	2	2	1	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	2	0	4	0	2	0	12	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	112	5	240	18	31	2	12	3	0	0		
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	47	2	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
	C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	12975	644	111	6	121	18	112	14	7	0	31	1	3	1	168	14
Small cell carcinoma	203	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non-small cell carcinoma	83	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1451	58	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Basal cell carcinoma	2174	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	342	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6411	241	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified carcinomas	106	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcinoma, unspecified	75	124	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant thymoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	583	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrosarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	22	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant complex mixed and stromal tumors	79	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	35	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	89	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	150	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	5	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant meningioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	395	28	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hodgkin lymphoma	47	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Plasma cell tumors	111	6	111	6	0	0	0	0	0	0	0	0	0	0	0	0
Chronic lymphoid leukemia	86	16	0	0	86	16	0	0	0	0	0	0	0	0	0	0
Leukemia except chronic lymphoid	157	17	0	0	35	2	112	14	7	0	0	0	3	1	0	0
Other lymphoreticular neoplasms	6	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0
Chronic myeloproliferative diseases	105	1	0	0	0	0	0	0	0	0	31	1	0	0	74	0
Myelodysplastic syndromes	88	14	0	0	0	0	0	0	0	0	0	0	0	0	88	14
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	1	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2015.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C00 – C80	Vse lokacije All sites	M+Ž	13208	7130	54,0	3480	26,3	2409	18,2	189	1,4
		M	7274	3863	53,1	1979	27,2	1328	18,3	104	1,4
C00	Ustnica Lip	M	14	13	–	1	–	0	–	0	–
		Ž	14	14	–	0	–	0	–	0	–
C01	Baza jezika Base of tongue	M	21	1	4,8	19	90,5	1	4,8	0	0
		Ž	7	1	–	5	–	1	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	29	11	37,9	18	62,1	0	0	0	0
		Ž	3	1	–	2	–	0	–	0	–
C03	Dlesen Gum	M	9	1	–	8	–	0	–	0	–
		Ž	5	0	–	5	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	28	10	35,7	17	60,7	1	3,6	0	0
		Ž	6	2	–	4	–	0	–	0	–
C05	Nebo Palate	M	14	6	–	8	–	0	–	0	–
		Ž	3	2	–	1	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	4	–	8	–	0	–	0	–
		Ž	7	2	–	5	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	8	1	–	7	–	0	–	0	–
		Ž	6	3	–	3	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C09	Tonzila Tonsil	M	43	5	11,6	37	86,0	1	2,3	0	0
		Ž	10	1	–	9	–	0	–	0	–
C10	Orofarinks Oropharynx	M	35	3	8,6	28	80,0	4	11,4	0	0
		Ž	6	1	–	5	–	0	–	0	–
C11	Nazofarinks Nasopharynx	M	8	1	–	7	–	0	–	0	–
		Ž	1	0	–	1	–	0	–	0	–
C12	Piriformni sinus Pyriform sinus	M	41	4	9,8	34	82,9	3	7,3	0	0
		Ž	1	0	–	1	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	24	1	4,2	23	95,8	0	0	0	0
		Ž	4	2	–	2	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	69	5	7,2	38	55,1	21	30,4	5	7,2
		Ž	23	5	21,7	10	43,5	7	30,4	1	4,3
C16	Želodec Stomach	M	296	50	16,9	132	44,6	108	36,5	6	2,0
		Ž	158	36	22,8	54	34,2	61	38,6	7	4,4
C17	Tanko črevo Small intestine	M	18	8	44,4	6	33,3	4	22,2	0	0
		Ž	18	4	22,2	8	44,4	4	22,2	2	11,1
C18	Debelo črevo Colon	M	469	100	21,3	247	52,7	117	24,9	5	1,1
		Ž	382	87	22,8	191	50,0	99	25,9	5	1,3
C19	Rektosigmoidna zveza Rectosigmoid junction	M	65	11	16,9	33	50,8	21	32,3	0	0
		Ž	47	11	23,4	21	44,7	15	31,9	0	0
C20	Rektum Rectum	M	248	48	19,4	143	57,7	54	21,8	3	1,2
		Ž	140	29	20,7	69	49,3	38	27,1	4	2,9
C21	Anus in analni kanal Anus and anal canal	M	3	1	–	1	–	1	–	0	–
		Ž	13	2	–	9	–	1	–	1	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	161	62	38,5	49	30,4	44	27,3	6	3,7
		Ž	51	12	23,5	13	25,5	21	41,2	5	9,8
C23	Žolčnik Gallbladder	M	23	4	17,4	6	26,1	12	52,2	1	4,3
		Ž	37	8	21,6	6	16,2	22	59,5	1	2,7
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	8	14,8	30	55,6	13	24,1	3	5,6
		Ž	67	13	19,4	29	43,3	18	26,9	7	10,4
C25	Trebušna slinavka Pancreas	M	192	13	6,8	62	32,3	112	58,3	5	2,6
		Ž	199	22	11,1	66	33,2	105	52,8	6	3,0
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	–	0	–	2	–	0	–
		Ž	1	0	–	0	–	1	–	0	–

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	7	1	—	6	—	0	—	0	—
		Ž	4	2	—	2	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	1	—	3	—	0	—	0	—
		Ž	2	0	—	2	—	0	—	0	—
C32	Grlo Larynx	M	83	38	45,8	44	53,0	0	0	1	1,2
		Ž	7	5	—	1	—	1	—	0	—
C33	Sapnik Trachea	M	2	1	—	0	—	1	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	970	151	15,6	296	30,5	513	52,9	10	1,0
		Ž	458	86	18,8	119	26,0	242	52,8	11	2,4
C37	Timus Thymus	M	2	1	—	1	—	0	—	0	—
		Ž	2	2	—	0	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	2	—	1	—	1	—	0	—
		Ž	3	1	—	0	—	2	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	5	3	—	1	—	1	—	0	—
		Ž	4	1	—	0	—	2	—	1	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	7	0	—	4	—	3	—	0	—
		Ž	5	1	—	2	—	2	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	290	213	73,4	71	24,5	4	1,4	2	0,7
		Ž	245	193	78,8	46	18,8	6	2,4	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1397	1381	98,9	13	0,9	2	0,1	1	0,1
		Ž	1282	1272	99,2	5	0,4	2	0,2	3	0,2
C45	Mezoteliom Mesothelioma	M	30	10	33,3	8	26,7	7	23,3	5	16,7
		Ž	9	3	—	5	—	1	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	3	3	—	0	—	0	—	0	—
		Ž	3	1	—	1	—	0	—	1	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	5	1	—	3	—	1	—	0	—
		Ž	17	1	5,9	10	58,8	6	35,3	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	31	11	35,5	12	38,7	5	16,1	3	9,7
		Ž	25	7	28,0	11	44,0	7	28,0	0	0
C50	Dojka Breast	M	8	3	—	4	—	1	—	0	—
		Ž	1315	708	53,8	509	38,7	94	7,1	4	0,3
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	58	36	62,1	21	36,2	1	1,7	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	10	3	—	6	—	1	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	119	51	42,9	54	45,4	14	11,8	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	355	270	76,1	60	16,9	17	4,8	8	2,3
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	14	6	—	5	—	2	—	1	—
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	148	17	11,5	19	12,8	112	75,7	0	0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	36	4	11,1	11	30,6	19	52,8	2	5,6
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	2	1	—	0	—	1	—	0	—
C60	Penis Penis	M	18	9	50,0	8	44,4	1	5,6	0	0
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1589	1092	68,7	395	24,9	80	5,0	22	1,4
		Ž	—	—	—	—	—	—	—	—	—

Nadaljevanje —>
Continued —>

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C62	Modo Testis	M	144	107	74,3	28	19,4	8	5,6	1	0,7
		Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	1	1	—	0	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	227	125	55,1	46	20,3	54	23,8	2	0,9
		Ž	105	65	61,9	24	22,9	16	15,2	0	0
C65	Ledvični meh Renal pelvis	M	14	6	—	5	—	3	—	0	—
		Ž	15	3	20,0	9	60,0	3	20,0	0	0
C66	Sečevod Ureter	M	2	1	—	1	—	0	—	0	—
		Ž	4	3	—	0	—	1	—	0	—
C67	Sečni mehur Bladder	M	249	183	73,5	47	18,9	16	6,4	3	1,2
		Ž	87	59	67,8	24	27,6	3	3,4	1	1,1
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	1	—	0	—	1	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C69	Okoli očesni adneksi Eye and adnexa	M	14	13	—	1	—	0	—	0	—
		Ž	15	12	80,0	3	20,0	0	0	0	0
C70	Meninge Meninges	M	3	2	—	0	—	1	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C71	Možgani Brain	M	98	98	100	0	0	0	0	0	0
		Ž	75	75	100	0	0	0	0	0	0
C72	Hrbtne možgane, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	1	1	—	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	55	32	58,2	18	32,7	4	7,3	1	1,8
		Ž	150	118	78,7	25	16,7	7	4,7	0	0
C74	Nadledvična žleza Adrenal gland	M	0	0	—	0	—	0	—	0	—
		Ž	1	0	—	0	—	1	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	1	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	4	0	—	1	—	3	—	0	—
		Ž	10	0	—	7	—	2	—	1	—
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	19	0	0	0	0	0	0	19	100
		Ž	13	0	—	0	—	0	—	13	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	26	0	0	0	0	26	100	0	0
		Ž	53	0	0	0	0	53	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	11	0	—	0	—	11	—	0	—
		Ž	9	0	—	0	—	9	—	0	—
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	62	0	0	0	0	62	100	0	0
		Ž	61	0	0	0	0	61	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C81	Hodgkinova bolezen Hodgkin's disease	M	29	7	24,1	9	31,0	12	41,4	1	3,4
		Ž	20	1	5,0	9	45,0	8	40,0	2	10,0
C82– C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	217	45	20,7	30	13,8	119	54,8	23	10,6
		Ž	206	40	19,4	26	12,6	115	55,8	25	12,1

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2015.

Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2015.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vsi NHL	M+Ž	423	0	1	1	2	2	3	6	6	7	13	20	39	51	51	56	68	97
	All NHL	M	217	0	1	1	1	2	2	5	4	3	7	11	21	30	21	32	38	38
		Ž	206	0	0	0	1	0	1	1	2	4	6	9	18	21	30	24	30	59
142	Slinavke Salivary glands	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0
		Ž	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1
145	Usta, drugo Mouth, other parts	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
146	Orofarinks Oropharynx	M	7	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	1	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0
147	Epifarinks Epipharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
151	Želodec Stomach	M	16	0	0	0	0	1	0	0	0	0	2	0	1	3	1	2	1	5
		Ž	11	0	0	0	0	0	0	0	1	0	1	1	1	0	1	2	2	2
152	Tanko črevo Small intestine	M	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1
153	Debelo črevo Colon	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2
161	Grlo Larynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	4	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	0
		Ž	4	0	0	0	0	0	0	0	0	1	1	0	0	1	0	1	0	0
163	Plevra, mediastinum, drugo Pleura, mediastinum, etc.	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
170	Kosti Bone	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
171	Mehka tkiva Soft tissues	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
173	Koža, drugi malignomi Skin, other malignancies	M	4	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	1	0
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	3
174	Dojka Breast	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
182	Maternica, telo, drugo Uterus, corpus, etc.	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
186	Modo Testis	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
190	Oko Eye	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	3
		Ž	4	0	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	1
191	Možgani Brain	M	7	0	0	0	0	0	0	0	0	0	0	0	1	2	2	2	2	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	3
193	Ščitnica Thyroid	M	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1
194	Endokrine žleze, druge Endocrine glands, other	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
202	Bezgavke Lymph nodes	M	160	0	1	1	1	1	2	4	3	1	3	9	18	24	15	24	29	24
		Ž	150	0	0	0	1	0	1	0	0	2	3	6	14	15	26	16	26	40

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu, Slovenija 2015.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex, Slovenia 2015.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Vse vrste All types	M+Ž M Ž	734 391 343	35,6 38,2 33,0
9727, 9728, 9835, 9836, 9811–9818	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	M Ž	10 12	1,0 1,2
9835, 9836, 9811	Limfoblastni limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	M Ž	8 11	0,8 1,1
9812	Limfoblastni limfom B / levkemija B z rekurentnimi citogenetskimi anomalijami B lymphoblastic lymphoma / leukaemia with recurrent genetic abnormalities	M Ž	2 1	0,2 0,1
9729, 9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	M Ž	4 0	0,4 0,0
9837	Limfoblastni limfom T / levkemija T T lymphoblastic lymphoma / leukaemia	M Ž	4 0	0,4 0,0
9591–9597, 9670–9699, 9712, 9731–9738, 9760–9764, 9823, 9826, 9833, 9940	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	M Ž	323 290	31,6 27,9
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	M Ž	68 50	6,7 4,8
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	M Ž	7 6	0,7 0,6
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	M Ž	3 7	0,3 0,7
9940	Dlakastocelična levkemija Hairy cell leukaemia	M Ž	5 1	0,5 0,1
9671	Limfoplazmatični limfom Lymphoplasmacytic lymphoma	M Ž	5 3	0,5 0,3
9732, 9733	Multipli mielom Plasma cell myeloma	M Ž	57 58	5,6 5,6
9731, 9734	Solitarni kostni in zunajkostni plazmatom Solitary plasmacytoma of bone and extraosseous	M Ž	2 0	0,2 0,0
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	M Ž	16 15	1,6 1,4
9699, ektranodalni	B-celični limfom robne cone, ektranodalni Marginal zone B-cell lymphoma, extranodal	M Ž	10 17	1,0 1,6
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	M Ž	6 2	0,6 0,2
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	M Ž	20 19	2,0 1,8
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	M Ž	5 7	0,5 0,7
9673	Limfom plaščnih celic Mantle cell lymphoma	M Ž	19 12	1,9 1,2
9735	Plazmablastni limfom Plasmablastic lymphoma	M Ž	2 0	0,2 0,0
9680	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL ČŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	M Ž	93 92	9,1 8,8
9687, 9826	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	M Ž	3 1	0,3 0,1
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	M Ž	1 0	0,1 0,0

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
9737	ALK-pozitivni velikocelični limfom B ALK positive large B-cell lymphoma	M	1	0,1
		Ž	0	0,0
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	M	19	1,9
		Ž	16	1,5
9827, 9831, 9834, 9948	Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	M	2	0,2
		Ž	0	0,0
9831	Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	M	1	0,1
		Ž	0	0,0
9834	Prolimfocitna levkemija T T-cell prolymphocytic leukaemia	M	1	0,1
		Ž	0	0,0
9700, 9701, 9708, 9709, 9716–9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	M	5	0,5
		Ž	3	0,3
9719	Ekstranodalni limfom NK/T, nazalni Extranodal NK/T-cell lymphoma, nasal type	M	0	0,0
		Ž	1	0,1
9716	Hepatosplenični gama delta limfom T Hepatosplenic gamma delta T-cell lymphoma	M	1	0,1
		Ž	0	0,0
9700	Fungoidna mikoza Mycosis fungoides	M	4	0,4
		Ž	1	0,1
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	M	0	0,0
		Ž	1	0,1
9702, 9705, 9714	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	M	12	1,2
		Ž	13	1,2
9702	Periferni limfom T (BDO- in ALK-negativni ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	M	3	0,3
		Ž	7	0,7
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M	4	0,4
		Ž	3	0,3
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	M	5	0,5
		Ž	3	0,3
9650–9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	M	29	2,8
		Ž	20	1,9
9659	HL z nodularno limfocitno predomnanco Nodular lymphocyte predominant HL	M	3	0,3
		Ž	1	0,1
9650	Klasični HL Classical HL	M	1	0,1
		Ž	8	0,8
9663, 9664, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	M	7	0,7
		Ž	5	0,5
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	M	17	1,7
		Ž	6	0,6
9653, 9654	Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL	M	1	0,1
		Ž	0	0,0
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukaemia	M	2	0,2
		Ž	3	0,3
9590	Maligni limfom, BDO Malignant lymphoma, NOS	M	2	0,2
		Ž	3	0,3
9750–9759	Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	M	4	0,4
		Ž	2	0,2
9750	Maligna histiocitoza Malignant histiocytosis	M	1	0,1
		Ž	0	0,0
9751	Histiocitoza Langerhansovih celic, NOS Langerhans cell histiocytosis, NOS	M	3	0,3
		Ž	1	0,1
9758	Sarkom folikularnih dendritičnih celic Follicular dendritic cell sarcoma	M	0	0,0
		Ž	1	0,1

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated**		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	14287	11604	81,2	9018	63,1	4027	28,2	3194	22,4
C00–C14	Usta in žrelo Mouth and pharynx	359	338	94,2	199	55,4	26	7,2	263	73,3
C15	Požiralnik Oesophagus	92	61	66,3	18	19,6	40	43,5	50	54,3
C16	Želodec Stomach	454	285	62,8	230	50,7	143	31,5	87	19,2
C18	Debelo črevo Colon	851	729	85,7	705	82,8	203	23,9	7	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	500	424	84,8	370	74,0	155	31,0	188	37,6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	212	87	41,0	42	19,8	49	23,1	4	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	181	67	37,0	62	34,3	9	–	1	–
C25	Trebušna slinavka Pancreas	391	144	36,8	80	20,5	79	20,2	7	–
C32	Grlo Larynx	90	83	92,2	48	53,3	2	–	65	72,2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1432	1030	71,9	320	22,3	458	32,0	629	43,9
C43	Maligni melanom kože Malignant melanoma of skin	535	530	99,1	526	98,3	3	–	31	5,8
C44	Druge maligne neoplazme kože Skin, other malignomas	2679	2606	97,3	2499	93,3	11	–	109	4,1
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	78	70	89,7	57	73,1	22	28,2	29	37,2
C50	Dojka Breast	1323	1283	97,0	1133	85,6	1182	89,3	818	61,8
C53	Maternični vrat Cervix uteri	119	112	94,1	82	68,9	8	–	66	55,5
C54	Maternično telo Corpus uteri	355	329	92,7	319	89,9	33	9,3	96	27,0
C56	Jajčnik Ovary	148	133	89,9	118	79,7	111	75,0	1	–
C61	Prostata Prostate	1589	1179	74,2	855	53,8	394	24,8	183	11,5
C62	Modo Testis	144	142	99	142	98,6	84	58,3	0	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	361	290	80,3	270	74,8	30	8,3	13	–
C67	Sečni mehur Bladder	336	311	92,6	307	91,4	44	13,1	19	5,7
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	179	145	81,0	125	69,8	72	40,2	108	60,3
C73	Ščitnica Thyroid gland	205	194	94,6	187	91,2	190	92,7	115	56,1
C81	Hodgkinova bolezen Hodgkin's disease	49	42	85,7	3	–	38	77,6	25	51,0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	423	296	70,0	45	10,6	217	51,3	116	27,4
C90	Difuzni plazmocitov in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	117	92	78,6	4	–	89	76,1	18	15,4
C91–C95	Levkemije Leukaemias	308	155	50,3	0	–	154	50,0	9	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by surgery during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Brežice	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica dr. Jožeta Potrča Ptuj	Splošna bolnišnica Slovenj Gradec	Splošna bolnišnica Trbovlje	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions***
C00–C96	Vse lokacije All sites	14287	9018	30	783	176	279	133	2704	1265	1258	377	360	438	31	504	36	587	57
C00–C14	Usta in žrelo Mouth and pharynx	359	199	0	4	0	1	0	131	0	58	3	0	1	0	0	0	1	0
C15	Požiralnik Oesophagus	92	18	0	0	0	0	0	17	0	1	0	0	0	0	0	0	0	0
C16	Želodec Stomach	454	230	0	3	0	5	6	109	2	78	7	10	2	0	5	0	3	0
C18	Debelo črevo Colon	851	705	6	56	1	61	23	237	48	90	32	38	25	12	36	17	23	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	500	370	3	16	0	21	16	88	75	66	16	9	25	4	16	5	10	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	212	42	0	0	0	0	1	25	0	15	0	0	0	0	0	0	0	1
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	181	62	1	0	0	0	1	31	0	23	2	0	0	1	0	0	3	0
C25	Trebušna slinavka Pancreas	391	80	0	0	0	1	6	45	0	28	0	0	0	0	0	0	0	0
C32	Grlo Larynx	90	48	0	0	0	0	0	37	0	10	1	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1432	320	0	0	159	0	0	105	0	55	0	0	1	0	0	0	0	0
C43	Maligni melanom kože Malignant melanoma of skin	535	526	9	59	0	44	13	129	26	56	19	17	33	6	10	2	80	23
C44	Druge maligne neoplazme kože Skin, other malignomas	2679	2499	6	313	1	135	18	694	22	196	184	110	230	2	114	2	464	8
C48–C49	Vežavno in mehko tkivo Connective and soft tissue	78	57	0	5	0	0	0	20	24	3	3	1	0	0	0	0	1	0
C50	Dojka Breast	1323	1133	0	20	0	0	1	4	820	181	3	72	0	0	27	0	0	5
C53	Maternični vrat Cervix uteri	119	82	1	7	0	1	0	55	1	4	3	1	1	1	0	1	0	6
C54	Maternično telo Corpus uteri	355	319	1	23	0	6	6	146	40	43	17	4	13	1	13	5	0	1
C56	Jajčnik Ovary	148	118	1	7	0	1	1	49	23	31	1	1	0	0	2	0	0	1
C61	Prostata Prostate	1589	855	0	198	0	0	12	167	0	101	48	57	51	0	218	0	1	2
C62	Modo Testis	144	142	0	18	0	0	10	61	0	23	6	10	8	0	5	0	0	1
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	361	270	0	19	1	0	3	126	0	49	15	11	19	0	27	0	0	0
C67	Sečni mehur Bladder	336	307	0	20	0	0	10	150	0	58	12	9	24	0	22	0	0	2
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	179	125	0	1	0	0	0	90	0	32	0	0	0	0	0	0	0	2
C73	Ščitnica Thyroid gland	205	187	0	5	12	0	1	26	135	8	0	0	0	0	0	0	0	0
C81	Hodgkinova bolezen Hodgkin's disease	49	3	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	423	45	0	1	1	1	0	22	5	5	1	2	4	0	2	0	0	1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	117	4	0	0	0	0	0	3	0	1	0	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	308	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2015, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po lokaciji raka in bolnici zdravljenja.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2015, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	14287	4027	95	167	19	450	2535	495	21	109	25	67	30	14
C00–C14	Usta in žrelo Mouth and pharynx	359	26	0	0	0	0	26	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	92	40	0	0	0	0	39	0	0	1	0	0	0	0
C16	Želodec Stomach	454	143	3	0	0	15	93	29	0	1	0	2	0	0
C18	Debelo črevo Colon	851	203	14	0	0	7	144	22	0	8	0	8	0	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	500	155	3	0	0	3	139	6	0	2	0	2	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	212	49	3	0	0	34	2	10	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	181	9	1	0	0	4	0	4	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	391	79	2	0	0	26	29	21	0	1	0	0	0	0
C32	Grlo Larynx	90	2	0	0	0	0	2	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1432	458	0	149	0	0	229	78	0	0	0	0	0	2
C43	Maligni melanom kože Malignant melanoma of skin	535	3	0	0	0	0	3	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2679	11	0	0	0	4	3	3	0	0	0	0	1	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	78	22	0	0	0	3	16	3	0	0	0	0	0	0
C50	Dojka Breast	1323	1182	24	1	3	0	875	206	0	48	0	20	0	5
C53	Maternični vrat Cervix uteri	119	8	0	0	0	0	7	1	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	355	33	0	0	0	0	29	4	0	0	0	0	0	0
C56	Jajčnik Ovary	148	111	1	0	0	0	81	28	0	1	0	0	0	0
C61	Prostata Prostate	1589	394	20	0	8	59	150	32	16	30	15	34	29	1
C62	Modo Testis	144	84	0	0	0	2	80	0	0	0	0	0	0	2
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	361	30	0	0	0	4	26	0	0	0	0	0	0	0
C67	Sečni mehur Bladder	336	44	0	0	1	7	33	1	0	0	2	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	179	72	0	0	0	2	70	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	205	190	5	12	1	24	140	8	0	0	0	0	0	0
C81	Hodgkinova bolezen Hodgkin's disease	49	38	0	0	0	3	35	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	423	217	3	0	2	17	188	3	1	3	0	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	117	89	5	0	3	49	0	14	3	6	5	1	0	3
C91–C95	Levkemije Leukaemias	308	154	8	1	0	122	2	13	1	5	2	0	0	0

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2015.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2015.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	
C00 – C96	Vse lokacije All sites	M+Ž	11703	32835	27480	36871	102393
		M	6287	16989	13110	13306	46168
C00–C14	Usta in žrelo Mouth and pharynx	Ž	5416	15846	14370	23565	56225
		M	258	537	416	452	1663
C15	Požiralnik Oesophagus	Ž	69	182	173	255	679
		M	54	50	15	21	140
C16	Želodec Stomach	Ž	15	10	9	9	43
		M	190	378	229	377	1174
C18	Debelo črevo Colon	Ž	105	207	176	343	831
		M	386	1206	940	900	3432
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	306	887	810	1006	3009
		M	281	1008	797	773	2859
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	155	526	572	715	1968
		M	81	85	25	17	208
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	24	21	7	9	61
		M	35	58	28	29	150
C25	Trebušna slinavka Pancreas	Ž	53	60	42	30	185
		M	81	66	23	13	183
C32	Grlo Larynx	Ž	88	70	25	21	204
		M	73	239	233	319	864
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	5	33	31	53	122
		M	583	631	341	348	1903
C43	Maligni melanom kože Malignant melanoma of skin	Ž	322	424	214	166	1126
		M	280	908	712	754	2654
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	240	880	906	1279	3305
		M	1377	4260	3347	3573	12557
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	Ž	1266	4331	3717	4522	13836
		M	30	76	61	185	352
C50	Dojka Breast	Ž	36	98	66	198	398
		M	8	42	20	36	106
C53	Maternični vrat Cervix uteri	Ž	1267	4317	4134	6761	16479
		M	–	–	–	–	–
C54	Maternično telo Corpus uteri	Ž	107	356	468	2576	3507
		M	–	–	–	–	–
C56	Jajčnik Ovary	Ž	334	1036	972	2218	4560
		M	–	–	–	–	–
C61	Prostata Prostate	Ž	127	346	274	858	1605
		M	1507	5004	3826	1815	12152
C62	Modo Testis	Ž	–	–	–	–	–
		M	143	408	479	1306	2336
C64–C65	Ledvica z ledvičnim mehcom Kidney with renal pelvis	Ž	–	–	–	–	–
		M	185	615	538	548	1886
C67	Sečni mehur Bladder	Ž	99	327	271	427	1124
		M	195	540	330	389	1454
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	72	157	109	149	487
		M	71	102	71	189	433
C73	Ščitnica Thyroid gland	Ž	46	71	61	146	324
		M	49	144	118	218	529
C81	Hodgkinova bolezen Hodgkin's disease	Ž	146	442	541	866	1995
		M	26	67	109	337	539
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	20	86	91	317	514
		M	183	479	329	489	1480
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	153	482	352	510	1497
		M	47	129	83	39	298
C91–C95	Levkemije Leukaemias	Ž	44	126	70	36	276
		M	119	326	245	351	1041
		Ž	104	254	180	318	856

* Pri posameznih lokacijah je pri prikazu prevalenca oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2015.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00 – C97	Vse lokacije All sites	M+Ž	6216	2	2	1	4	1	4	22	34	53	119	256	448	677	739	851	975	2028	
		M	3484	2	2	0	4	0	4	9	13	25	56	159	274	427	447	518	583	961	
	Ž	2732	0	0	1	0	1	0	13	21	28	63	97	174	250	292	333	392	1067		
C00	Ustnica Lip	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C01	Baza jezika Base of tongue	M	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	9	0	0	0	0	0	0	0	0	0	0	1	3	2	1	1	1	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C03	Dlesen Gum	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C04	Ustno dno Floor of mouth	M	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C05	Nebo Palate	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	7	0	0	0	0	0	0	0	0	0	1	2	0	2	2	0	0	0	
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	0	2
C07	Parotidna žleza Parotid gland	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C09	Tonzila Tonsil	M	3	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Orofarinks Oropharynx	M	57	0	0	0	0	0	0	0	0	1	1	4	9	13	10	7	9	3	
		Ž	8	0	0	0	0	0	0	0	0	0	0	2	0	0	3	0	1	2	0
C11	Nazofarinks Nasopharynx	M	4	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C12	Piriformni sinus Pyriform sinus	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C13	Hipoфарinks Hypopharynx	M	25	0	0	0	0	0	0	0	0	1	1	5	4	3	4	2	2	3	
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	7	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	3	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C15	Požiralnik Oesophagus	M	73	0	0	0	0	0	0	0	0	0	0	8	13	13	9	7	11	12	
		Ž	15	0	0	0	0	0	0	0	1	0	1	0	1	3	3	0	2	4	0
C16	Želodec Stomach	M	217	0	0	0	0	0	0	0	1	2	4	9	23	19	26	31	42	60	
		Ž	127	0	0	0	0	0	0	2	0	0	1	6	11	9	8	12	22	56	0
C17	Tanko črevo Small intestine	M	11	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	1	3	
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	6
C18	Debelo črevo Colon	M	265	0	0	0	0	0	0	1	1	6	3	11	20	25	23	50	43	82	
		Ž	209	0	0	0	0	0	0	0	1	1	5	4	9	13	20	25	31	100	0
C19	Rektosigmoidna zveza Rectosigmoid junction	M	24	0	0	0	0	0	0	0	0	1	2	3	1	1	5	3	8	9	
		Ž	23	0	0	0	0	0	0	1	0	0	0	0	0	4	3	1	5	9	0
C20	Rektum Rectum	M	166	0	0	0	0	0	1	0	0	2	4	9	12	21	20	21	29	47	
		Ž	95	0	0	0	0	0	0	0	1	1	4	1	1	7	10	10	17	43	0
C21	Anus in analni kanal Anus and anal canal	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	155	0	0	0	0	0	0	1	0	0	2	8	12	26	23	24	25	34	
		Ž	93	0	0	0	0	0	0	0	0	0	2	0	3	9	8	14	20	37	0
C23	Žolčnik Gallbladder	M	22	0	0	0	0	0	0	0	0	0	0	0	2	1	4	6	4	5	0
		Ž	28	0	0	0	0	0	0	0	0	0	0	1	1	2	6	6	4	8	0
C24	Drugi in neopredeljeni deli biliamega trakta Biliary tract, other and unspecified parts	M	20	0	0	0	0	0	0	0	0	0	0	0	0	4	2	1	5	8	0
		Ž	24	0	0	0	0	0	0	0	0	0	0	0	1	3	3	2	0	2	13
C25	Trebušna slinavka Pancreas	M	188	0	0	0	0	0	0	2	1	0	2	10	22	25	32	36	26	32	0
		Ž	185	0	0	0	0	0	0	1	1	0	4	4	6	16	17	30	38	68	0
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	3	0
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	10	0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1
C31	Obnosni sinusi Accessory sinuses	M	7	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0	3	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0
C32	Grlo Larynx	M	42	0	0	0	0	0	0	0	0	0	1	4	7	5	3	6	6	10	0
		Ž	9	0	0	0	0	0	0	0	0	0	0	1	1	2	1	0	3	1	0
C33	Sapnik Trachea	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C34	Sapnica in pljuča Bronchus and lung	M	847	0	0	0	0	0	1	1	1	2	11	44	85	141	158	118	138	147	
		Ž	358	0	0	0	0	0	0	0	0	1	2	6	16	46	61	47	49	45	85
C37	Timus Thymus	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	5	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	2	
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	5
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepnih hrustanec udov Bone and articular cartilage of limbs	M	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	
		Ž	3	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	1
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	2	
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1
C43	Malignni melanom kože Malignant melanoma of skin	M	69	0	0	0	0	0	0	0	0	1	3	6	5	12	9	6	10	17	
		Ž	61	0	0	0	0	0	0	2	3	1	1	3	2	8	6	16	5	14	
C44	Druge malignne neoplazme kože Skin, other malignomas	M	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	12	
		Ž	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	12	
C45	Mezoteliom Mesothelioma	M	18	0	0	0	0	0	0	0	0	2	1	4	2	2	4	1	2	2	
		Ž	10	0	0	0	0	0	0	0	0	1	0	1	0	3	1	1	1	3	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	4	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	16	1	0	0	0	0	0	0	0	1	1	2	1	4	2	2	2	2	
		Ž	18	0	0	0	0	0	0	0	1	0	1	1	3	2	3	1	6	6	
C50	Dojka Breast	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	
		Ž	431	0	0	0	0	0	0	1	8	9	15	24	32	37	48	36	46	175	
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	20	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	2	13	
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	6	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	3	
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	50	0	0	0	0	0	0	1	1	4	4	6	3	6	2	6	13	13	
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	66	0	0	0	0	0	0	0	0	0	1	1	1	5	7	15	15	21	
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	48	0	0	0	0	0	0	0	0	2	1	2	2	4	6	5	26	26	
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	150	0	0	0	0	0	1	1	3	10	10	11	16	23	21	17	37	37	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	8	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1	4	4
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	M	405	0	0	0	0	0	0	0	0	0	1	10	18	26	54	78	218	218	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	6	0	0	0	1	0	0	0	2	0	0	0	0	0	0	0	1	2	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	118	0	0	0	0	0	0	0	0	1	4	8	8	18	14	22	20	23	
		Ž	51	0	0	0	0	0	0	0	0	0	2	1	2	1	5	7	9	24	24
C65	Ledvični meh Renal pelvis	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	1	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0
C66	Sečevod Ureter	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	1	1	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1
C67	Sečni mehur Bladder	M	133	0	0	0	0	0	0	0	0	1	1	0	1	10	10	16	26	68	
		Ž	52	0	0	0	0	0	0	0	0	0	0	0	2	3	3	3	9	32	32
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

Nadaljevanje →
Continued →

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C70	Meninge Meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C71	Možgani Brain	M	99	0	0	0	1	0	0	3	3	5	5	10	7	19	15	11	10	10
		Ž	87	0	0	1	0	0	0	0	1	1	2	5	13	10	9	14	8	23
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	8	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	2
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	8
C74	Nadledvična žleza Adrenal gland	M	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	12	0	0	0	0	0	0	0	0	0	0	0	0	2	2	3	2	3
		Ž	28	0	0	0	0	0	0	0	0	0	0	0	0	2	0	3	6	17
C79	Metastaze, druge Metastases of other sites	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	28	0	0	0	0	0	0	0	0	1	0	3	4	4	6	3	7	7
		Ž	45	0	0	0	0	0	0	1	0	1	1	1	4	5	7	6	19	19
C81	Hodgkinova bolezen Hodgkin's disease	M	4	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	0
		Ž	5	0	0	0	0	0	0	0	1	1	0	0	0	0	1	1	0	1
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	27	0	0	0	0	0	0	1	0	1	0	1	4	5	4	5	6	6
		Ž	34	0	0	0	0	0	1	0	1	0	1	1	0	5	1	7	17	17
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	12	0	0	0	0	0	0	0	0	0	0	0	2	1	4	3	2	2
		Ž	12	0	0	0	0	0	0	0	0	0	0	0	1	2	1	2	6	6
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	32	0	0	0	0	0	1	0	0	1	0	2	3	1	2	4	9	9
		Ž	53	0	0	0	0	0	0	0	0	0	0	1	3	2	1	6	9	31
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	49	0	0	0	0	0	0	0	0	0	0	4	0	8	3	7	6	21
		Ž	58	0	0	0	0	0	0	0	0	0	0	3	3	2	8	9	10	23
C91	Limfatična levkemija Lymphoid leukaemia	M	46	0	1	0	1	0	0	0	0	1	0	1	2	3	4	6	6	21
		Ž	33	0	0	0	0	0	0	0	0	0	0	1	0	3	3	5	5	21
C92	Mieločna levkemija Myeloid leukaemia	M	55	1	1	0	0	0	0	0	0	0	1	2	1	3	6	11	11	18
		Ž	39	0	0	0	0	0	0	0	0	0	0	1	1	3	7	8	6	13
C93	Monocitna levkemija Monocytic leukaemia	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	4	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	8	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	3	2
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva Other & unspecified malignant neoplasms of lymphoid, haemopoetic & related tissues	M	26	0	0	0	1	0	0	0	1	0	0	1	1	2	1	6	3	10
		Ž	30	0	0	0	0	0	0	0	0	0	0	0	1	0	3	0	3	23
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independant (primary) multiple sites	M	78	0	0	0	0	0	0	0	0	0	1	1	2	9	9	10	19	27
		Ž	32	0	0	0	0	0	0	0	1	0	0	0	1	3	5	4	4	6
Zgoraj neupoštevani Not included above																				
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M	11	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3	1	5
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	0	1	3	1	2	3
D33	ČŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M	3	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D43	ČŽS, neopredeljeno CNS, uncertain or unknown	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2

Tabela 14: Eno-, tro- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2011–2015 po spolu.

Table 14: One-, three- and five-year net survival (with 95% confidence interval) of patients diagnosed with selected cancers in period 2011–2015 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje; 95 % IZ		Tro-letno preživetje; 95 % IZ		Pet-letno preživetje; 95 % IZ	
			One-year survival; 95% CI	Three-year survival; 95% CI	Three-year survival; 95% CI	Five-year survival; 95% CI		
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	73,3	72,9–73,7	61,5	61,0–62,0	57,2	56,6–57,7
		M	71,8	71,3–72,4	59,5	58,9–60,2	55,5	54,8–56,2
C00–C14	Usta in žrelo Mouth and pharynx	Ž	75,1	74,6–75,7	63,9	63,3–64,6	59,2	58,5–60,0
		M	74,0	71,6–76,4	52,6	49,7–55,5	44,4	41,3–47,7
C15	Požiralnik Oesophagus	Ž	83,2	79,2–87,4	70,8	65,6–76,4	63,3	56,4–71,0
		M	40,8	36,0–46,2	14,0	10,8–18,3	10,0	7,1–14,2
C16	Želodec Stomach	Ž	37,0	27,8–49,4	11,7	6,3–21,5	12,0	6,5–22,1
		M	52,0	49,4–54,7	33,5	30,9–36,3	29,3	26,5–32,3
C18	Debelo črevo Colon	Ž	47,0	43,7–50,6	32,9	29,7–36,5	30,4	27,0–34,2
		M	79,8	78,1–81,6	67,7	65,5–69,9	62,4	59,7–65,1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	Ž	75,4	73,3–77,5	63,9	61,5–66,5	60,1	57,2–63,2
		M	84,1	82,3–86,0	68,9	66,4–71,4	63,8	60,8–66,8
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	Ž	78,8	76,2–81,5	65,6	62,3–69	57,9	54,1–61,9
		M	31,7	28,4–35,4	14,8	12,3–17,9	8,5	6,1–11,8
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	Ž	30,1	24,7–36,6	10,9	7,4–15,9	5,1	2,5–10,4
		M	35,7	31,1–41,0	18,1	14,4–22,7	14,1	10,5–19,1
C25	Trebušna slinavka Pancreas	Ž	29,3	25,6–33,7	14,3	11,4–17,9	11,0	8,0–15,0
		M	21,6	19,1–24,5	7,4	5,8–9,4	5,6	4,1–7,6
C32	Grlo Larynx	Ž	22,7	20,0–25,7	8,6	6,9–10,8	5,3	3,8–7,4
		M	85,9	82,3–89,5	70,5	65,7–75,6	63,1	57,4–69,3
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	Ž	*	*	*	*	*	*
		M	39,3	37,8–40,8	19,0	17,8–20,3	14,6	13,4–15,9
C43	Malignan melanom kože Malignant melanoma of skin	Ž	49,1	47,0–51,4	27,4	25,5–29,5	20,8	18,8–22,9
		M	97,5	96,3–98,7	91,5	89,3–93,8	88,2	85–91,4
C44	Druge maligne neoplazme kože Skin, other malignomas	Ž	97,6	96,4–98,8	92,9	90,8–95,1	90,7	87,9–93,7
		M	**	**	**	**	**	**
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	Ž	**	**	**	**	**	**
		M	77,5	70,9–84,8	62,1	54,1–71,2	57,3	48,1–68,2
C50	Dojka Breast	Ž	77,1	71,3–83,3	57,6	50,8–65,3	48,7	41,4–57,3
		M	*	*	*	*	*	*
C53	Maternični vrat Cervix uteri	Ž	96,3	95,8–96,9	91,1	90,2–92,1	86,7	85,4–88,1
		M	–	–	–	–	–	–
C54	Maternično telo Corpus uteri	Ž	85,9	83,1–88,8	72,5	68,9–76,4	69,0	64,7–73,6
		M	–	–	–	–	–	–
C56	Jajčnik Ovary	Ž	92,2	90,7–93,6	84,3	82,2–86,5	80,5	77,8–83,2
		M	–	–	–	–	–	–
C61	Prostata Prostate	Ž	75,6	72,6–78,8	53,3	49,7–57,1	42,1	38,4–46,2
		M	96,8	96,2–97,3	93,3	92,4–94,3	91,7	90,3–93,1
C62	Modo Testis	Ž	–	–	–	–	–	–
		M	98,4	97,3–99,5	98,4	97,1–99,7	97,7	95,5–100,0
C64–C65	Ledvica z ledvičnim mehonom Kidney with renal pelvis	Ž	–	–	–	–	–	–
		M	79,0	76,5–81,5	68,8	65,8–72,0	65,3	61,8–69,0
C67	Sečni mehur Bladder	Ž	78,0	74,7–81,5	67,9	63,9–72,2	68,0	63,6–72,7
		M	74,9	72,2–77,7	62,4	59,1–65,8	56,7	52,6–61,1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	Ž	69,8	65,3–74,7	52,6	47,3–58,4	44,9	38,8–52,0
		M	48,1	43,6–53,1	23,9	20,2–28,4	20,1	16,4–24,6
C73	Ščitnica Thyroid gland	Ž	41,1	36,2–46,7	21,2	17,3–26,1	17,7	13,9–22,6
		M	93,1	89,5–96,9	89,7	84,8–94,8	89,7	83,9–95,9
C81	Hodgkinova bolezen Hodgkin's disease	Ž	96,7	95,2–98,3	95,7	93,6–97,8	95,9	93,4–98,4
		M	92,6	87,6–98,0	86,2	79,2–93,9	85,8	77,9–94,5
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	Ž	92,7	88,0–97,7	89,3	83,3–95,7	88,3	81,2–95,9
		M	78,0	75,2–80,8	67,6	64,3–71,2	65,4	61,4–69,7
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	Ž	76,1	73,3–79,0	66,7	63,3–70,2	61,8	57,9–65,8
		M	70,9	65,8–76,5	53,7	47,9–60,4	36,9	30,4–44,8
C91–C95	Levkemije Leukaemias	Ž	70,0	64,9–75,5	51,3	45,5–57,9	39,9	33,4–47,8
		M	64,3	60,9–67,8	53,6	49,9–57,6	46,3	42,0–51,0
		Ž	64,6	60,8–68,6	55,5	51,3–60,0	47,6	42,7–53,0

* Število v analizo vključenih bolnikov je povprečno letno manjše od 15

* Annual average number of patients included in the analysis is less than 15

** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo

** Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2013

- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Primic-Žakelj M, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. *International journal of cancer* 2013; 132: 1170–81.
- Gašljević G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gašparov S. HER2 in gastric cancer: and immunohistochemical study on tissue microarrays and the coresponding whole-tissue sections with a supplemental FISH study. *Pathol Oncol Res* 2013; 19: 855–65.
- Ivanuš U, Primic-Žakelj M, Žagar T, Florjančič M, Kuster M. Delovanje državnega presejalnega programa za raka materničnega vratu ZORA v osrednjeslovenski statistični regiji. In: Letnar Žbogar N, et al. *Zdravje v ljubljanski zdravstveni regiji 2012*. Ljubljana: Zavod za zdravstveno varstvo, 2013: 74–94.
- Ivanuš U, Primic-Žakelj M. Klinična uporaba in pomen testa za humani papilomski virus v Državnem presejalnem programu ZORA (Clinical use and value of human papillomavirus test in national cervical cancer screening programme ZORA). *Med Razgl* 2013; 52(3): 123–35.
- Ivanuš U, Primic-Žakelj M. Pomen izvida testa HPV v kolposkopski ambulanti. In: Smrkolj Š, ed. *Zbornik*. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2013: 78–101.
- Ivanuš U, Primic-Žakelj M. Uporaba triaznega testa HPV v programu ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. *Zbornik predavanj*. Ljubljana: Onkološki inštitut, 2013: 27–34.
- von Karsa L, Maučec-Zakotnik J, Primic-Žakelj M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013; 45, 51–9.
- Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Radiol Oncol* 2013; 47: 161–5.
- Krajc M, Šval C, Kadivec M, Hertl K, Primic-Žakelj M. Rezultati državnega presejalnega programa Dora v ljubljanski regiji. In: Letnar Žbogar N, et al. *Zdravje v ljubljanski zdravstveni regiji 2012*. Ljubljana: Zavod za zdravstveno varstvo, 2013: 66–73.
- Maver Vodičar P, Seme K, Korač T, Dimitrov G, Döbrössy L, Primic-Žakelj M, et al. Cervical cancer screening practices in central and eastern Europe in 2012. *Acta Dermatovenerol APA* 2013; 22: 7–19.
- Primic-Žakelj M, Ivanuš U. Deset let delovanja programa ZORA. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. *Zbornik predavanj*. Ljubljana: Onkološki inštitut, 2013: 7–11.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke. In: Šola tumorjev prebavil, Ljubljana, 30. 11. 2012. Ljubljana: Onkološki inštitut, 2013: 17–20.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka prostate, sečnega mehurja, ledvic in mod v Sloveniji. In: Novaković S, ed. *Izzivi v multidisciplinarni obravnavi bolnikov z rakom sečnega mehurja, prostate, ledvic in mod*. Zbornik. Ljubljana: Onkološki inštitut: Kancerološko združenje Slovenskega zdravniškega društva, 2013: 16–23.

- Primic-Žakelj M. Epidemiology of cancer diseases in different European regions and the importance of risk factors. In: Fourth International Medical Congress, 11–15 September 2013, Portorož, Slovenia, 2013: 49–51.
- Primic-Žakelj M, Ivanuš U, Žagar T. Neodzivnice DP DORA so bolj ogrožene z rakom materničnega vratu (Non-responders to the National Cervical Cancer Screening Programme Zora are at an increased risk of cervical cancer). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 29.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak dojke: zbolevnost, preživetje in dejavniki tveganja. In: Matković M, ed. Pacientke z rakom dojke - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2013: 5–13.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. In: Novosti v diagnostiki in zdravljenju raka, Ljubljana, 13. decembra 2013: ob jubilejni, 20. obletnici delovanja združenja Fundacija doc. dr. Josip Cholewa v sodelovanju z Medicinsko fakulteto Ljubljana, Kliničnim centrom Ljubljana in Onkološkim inštitutom Ljubljana. Ljubljana: Fundacija doc. dr. Josip Cholewa, 2013: 5–6.
- Zadnik V, Žagar T, Jarm K, Primic-Žakelj M. The evaluation of the mesothelioma epidemic in Slovenia. In: 35th International Association of Cancer Registries Conference, 22–24 October 2013, Buenos Aires. Programme & abstracts. Buenos Aires: The National Cancer Institute, 2013: 109.
- Zadnik V, Ivanuš U, Žagar T, Primic-Žakelj M. Pojavljanje raka na območju upravnih enot Celje in Šentjur pri Celju (Cancer incidence in administrative units Celje and Šentjur pri Celju). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 74.
- Znaor A, van den Hurk C, Primic-Žakelj M, Agius D, Coza D, Demetriou A, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. *Eur J Cancer* 2013; 49: 1683–91.
- Žagar T, Zadnik V, Primic-Žakelj M. Local estimation of standardized incidence ratio applied to Slovenian cancer data. V: International Conference Applied Statistics 2013, September 22–25, 2013, Ribno (Bled), Slovenia. Lusa L, Stare J, eds. Abstracts and program. Ljubljana: Statistical Society of Slovenia, 2013: 55.
- Žagar T, Primic-Žakelj M, Zadnik V. Zemljevidi raka, narejeni z metodo lokalno ocenjenega standardiziranega količnika (Cancer maps created with local standardized incidence ratio method). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 71.

2014

- Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. *J Eur Acad Dermatol Venereol* 2014; 28: 1170–8.
- Gutnik H, Matišič JP, Primic-Žakelj M, Strojjan Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001–2007. *Radiol Oncol* 2014; 48: 282–8.
- Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45–52.
- Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48–69.

- Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B, eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99–106.
- Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J, ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221–8.
- Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64–72.
- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. *Clinical genetics* 2014; 85: 59–63.
- Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novaković S, Ivanuš U, Primic-Žakelj M, et al. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36–40.
- Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6–7.
- Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A, eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249–55.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7–11.
- Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkoj Š, ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27–36.
- Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanecz A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1–4.
- Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J, ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115–24.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotvornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotvornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7–34.
- Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: European Union and European Network of Cancer Registries (ENCR). Towards a harmonised cancer information system in Europe, 2014: 71.
- Strojani P, Zadnik V, Šifer R, Lanišnik B, Didanovič V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. *Eur Arch Otorhinolaryngol* 2014: 1–7.
- Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. *Cancer investigation* 2014; 32: 99–104.

- Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, ed. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. Januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67–73.
- Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J, ed. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacolom Slovenija, združenje za boj proti raku debelega črevesa in danke, 2014: 22–4.
- Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Gajšek P, ed. Strokovni seminar Daljnovodi in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirana sevanja, 2014: 19–21.
- Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M, et al. Economic evaluation of cancer registration in Europe. *J Registry Manag* 2014; 41: 31–7.
- Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), 36th annual conference 2014. Ottawa, Canada, 26–28 June 2014. Ottawa: The National Cancer Institute, 2014: 109.

2015

- Allemani C, Weir HK, Carreira H, Harewood R, Primic-Žakelj M, Žagar T, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015; 385: 977–1010.
- Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Primic-Žakelj M, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. *Radiother Oncol* 2015; 116: 45–50.
- Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Primic-Žakelj M, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. *Radiother Oncol* 2015; 116: 38–44.
- Ivanuš U, Primic-Žakelj M. Test HPV doma za neodzivnice programa Zora: preliminarni rezultati. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana; 2015: 49–55.
- Ivanuš U, Primic-Žakelj M. Vloga triažnega testa HPV in kolposkopije v programu ZORA. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD in Onkološki inštitut, 2015: 35–52.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki in preprečevanje s cepljenjem. In: Novaković S, Zakotnik B, Žgajnar J, eds. Preprečevanje raka: dejstva, ki jih mora vedeti zdravstveni delavec: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2015: 89–102.
- Jarm K, Krajc M, Primic-Žakelj M, Šval C, Purić F, Kadivec M, et al. Presejanje za raka dojke: program Dora. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 70–5.
- Karalexi MA, Papatoma P, Thomopoulos TP, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumour mortality and survival in Southern and Eastern Europe (1983–2014): Gaps persist across 14 cancer registries. *Eur J Cancer* 2015; 51: 2665–77.
- Krajc M, Primic-Žakelj M. Dojenje, hormonska zdravila in drugi dejavniki, vpleteni v nastanek raka dojke. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 77–86.
- Papatoma P, Thomopoulos TP, Karalexi MA, Ryzhov A, Zborovskaya A, Žagar T, et al. Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries. *Eur J Cancer* 2015; 51: 1444–55.
- Primic-Žakelj M. Redke rakave bolezni. In: Modic K, ed. Redke bolezni: 28 februar 2015. Ljubljana: Društvo BKB, 2015: 35–40.

- Primic-Žakelj M. Kaj je evropski kodeks proti raku. In: Primic-Žakelj M, ed. Kaj sporoča prenovljeni evropski kodeks proti raku. Ljubljana: Zveza slovenskih društev za boj proti raku, 2015: 7–9.
- Primic-Žakelj M, Čeh F. Najpogostejši raki pri moških 2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Čeh F. 12 nasvetov proti raku : Evropski kodeks proti raku 2014–2015. Zveza slovenskih društev za boj proti raku, 2015.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP Zora - 2014/2015. In: Ivanuš U, Primic-Žakelj M, eds. Zbornik predavanj, 6 izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 6 november 2015. Ljubljana: Onkološki inštitut Ljubljana, 2015: 7–10.
- Primic-Žakelj M, Žagar T. Preprečevanje raka v ustni votlini. In: Artnik B, Premik M, Jovanovič K, eds. Zbornik člankov in izvlečkov, Kongres ob 40-letnici strokovnih srečanj stomatologov Slovenije [tudi] 40 srečanje stomatologov Slovenije "Iz prakse za prakso" in pridruženi 10 Cvahtetovi dnevi javnega zdravja "Skrb za ustno zdravje", Portorož, 4 do 6 junij 2015. Ljubljana: Stomatološka sekcija Slovenskega zdravniškega društva, 2015: 22-9.
- Rems M, Jarm K, Zadnik V, Primic-Žakelj M. Lokalna ponovitev boleznih pri bolnikih, operiranih zaradi nemetastatskega raka danke, zbolelih v obdobju 2003–2005 = Local recurrence of rectal cancer in patients with nonmetastatic disease, diagnosed in 2003–2005. Zdrav vest 2015; 84: 277-86.
- Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Holleccek B, Primic-Žakelj M, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2191–205.
- Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, Primic-Žakelj M, et al. Cancer survival in Europe, 2000–2007: Doing better, feeling worse? Eur J Cancer 2015; 51: 2101–3.
- Schuz J, Espina C, Villain P, Herrero R, Leon ME, Primic-Žakelj M, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer epidemiol 2015; 39 Suppl 1: S1-10.
- Strojjan P, Zadnik V, Sifer R, Lanisnik B, Didanovic V, Jereb S, et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. Eur Arch Otorhinolaryngol 2015; 272: 3805-14.
- Zadnik V. Epidemiologija raka jajčnika. In: Smrkolj S, Zobec Logar H, Šešek M, eds. Rak jajčnikov: zbornik. Ljubljana: Slovensko zdravniško društvo, Združenje za radioterapijo in onkologijo, 2015: 6–9.
- Zadnik V. Epidemiološki trendi hormonsko odvisnih rakov = Epidemiological trends of hormon related-cancers. In: Černe K, ed. Kemijski povzročitelji hormonskih motenj od molekule do človeka = Endocrine disrupting chemicals - from molecule to man. Ljubljana: Slovensko toksikološko društvo, 2015: 22.
- Zanetti R, Schmidtman I, Sacchetto L, Binder-Foucard F, Bordoni A, Zadnik V, et al. Completeness and timeliness: Cancer registries could/should improve their performance. European journal of cancer. 2015; 51: 1091-8.
- Zwitter M, Žagar T. Zdravljenje pljučnega raka: perspektiva dveh desetletij. In: Kovač V, Rajer M, eds. Prva šola pljučnega raka. Ljubljana: Slovensko zdravniško društvo, 2015: 116-20.

2016

- Avbelj M, Zupanc D, Žagar T, Kotnik P, Jakil M, Pirnat E, et al. Rak ščitnice pri otrocih. In: Bešič N, Zaletel K, eds. Dan ščitnice. Ljubljana: Slovenska sekcija za onkološko kirurgijo SZD, 2016: 27.
- Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Primic-Žakelj M, et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer. 2016; 55: 47–55.
- de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Primic-Žakelj M, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Eur J Surg Oncol. 2016; 42: 1414-9.
- Deandrea S, Molina-Barcelo A, Uluturk A, Primic-Žakelj M, Jarm K, Krajc M, et al. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. Prev Med. 2016; 91: 250-63.

- Ivanuš U, Primic Žakelj M, Jerman T, Florjančič M, Kuster M, Takac I, et al. HPV self-sampling response rate in randomised study among Slovenian non-responders to the organised cervical cancer screening program. In: EUROGIN 2016 abstracts: part I - main conference program. Salzburg: EUROGIN, 2016: 333-4.
- Ivanuš U, Učakar V. Okužbam pripisljivi raki: novi pristopi v primarni in sekundarni preventivi. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 106-7.
- Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Žagar T, et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. *Eur J Cancer*. 2016; 67: 183-90.
- Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Žagar T, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. *Hematol Oncol*. Epub ahead of print.
- Kokalj M, Zadnik V, Ančin A, Plavc G, Didanović V, Šifrer R, et al. Ploščatocelični karcinom neznanega izvora z zasevki v bezgavkah na vratu: vloga elektivnega obsevanja sluznice v področju glave in vratu = Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: the role of elective irradiation of mucosal sites. *Med Razgl*. 2016; 55(S1): 297-301.
- Krajc M, Zadnik V. Razvoj in implementacija orodja za določanje individualne ogroženosti z rakom dojk v slovenski populaciji. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 116-7.
- Mandelj N, Zadnik V. Breme želodčnega raka v Sloveniji z oceno pripisljivih deležev zaradi prekomernega vnosa soli ter prenizkega vnosa sadja in zelenjave. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 119-20.
- Primic Žakelj M. Prenovljen evropski kodeks proti raku = New edition of European code against cancer. *Gastroenterolog*. 2016; 20(S2): 5-11.
- Primic Žakelj M, Ivanuš U. Zgodnje odkrivanje raka materničnega vratu - program Zora = Screening for cervical cancer in Slovenia - programme Zora. *Gastroenterolog*. 2016; 20(S2): 72-7.
- Primic Žakelj M, Ivanuš U. Presejalni programi za raka. In: Novaković S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut; 2016. p. 14-23.
- Primic Žakelj M, Jarm K, Novak Mlakar D, Ivanuš U. Presejanje za raka: krhko ravnovesje med koristimi in škodo. In: Kraigher A, Berger T, Nikolič S, eds. Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 110-1.
- Primic Žakelj M, Žagar T. Epidemiologija raka dojk. In: Borštnar S, Duratović Konjević A, Grašič-Kuhar C, eds. Zbornik prispevkov, Šola raka dojk. Ljubljana: Združenje za senologijo, SZD, 2016: 6-11.
- Strojman P, Kokalj M, Zadnik V, Ančin A, Plavc G, Didanović V, et al. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation. *Eur Arch Otorhinolaryngol*. 2016; 273: 4561-9.
- Zadnik V. Onkološka epidemiologija čez desetletje. In: Novaković S, editor. Razvojni trendi v onkologiji - onkologija čez desetletje: izbrana poglavja in državni program obvladovanja raka 2017-2021: zbornik. Ljubljana: Kancerološko združenje Slovenskega zdravniškega društva: Onkološki inštitut, 2016: 9-13.
- Zadnik V. Raziskovanje vpliva okolja na zbolevanje za rakom in ocenjevanje tveganja. In: Belovič B, Čemažar M, Perharič L, Primic Žakelj M, Zadnik V, Zdešar A, eds. Kemikalije v okolju in rak. Ljubljana: Zveza slovenskih društev za boj proti raku, 2016: 7-18.
- Zadnik V, Ivanuš U. Epidemiologija raka materničnega telesa. In: Merlo S, Smrkolj Š, Šegedin B, eds. Rak materničnega telesa: zbornik. Ljubljana: Združenje za radioterapijo in onkologijo SZD: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2016: 15-9.
- Zadnik V, Krajc M. Epidemiological trends of hormone-related cancers in Slovenia. *Arh Hig Rada Toksikol*. 2016; 67: 83-92.

- Zadnik V, Žagar T, Jarm K, Primic Žakelj M. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961–2013. In: *Joining forces for better cancer registration in Europe*. Luxembourg: Publication Office of the European Union, 2016: 32.
- Zadnik V, Žagar T, Primic Žakelj M. Linkage to supplementary registration sources: key lessons learned in the last 30 years in Slovenia. In: Benider A, Zanetti R, Siesling S, Bray F, eds. *The 38th Annual IACR Conference*. Marrakech: IACR, 2016: 63.
- Zadnik V, Žagar T, Primic Žakelj M. Cancer Patients' Survival: Standard Calculation Methods And Some Considerations Regarding Their Interpretation. *Zdrav Varst.* 2016; 55: 134-41.
- Žagar T, Zadnik V, Jarm K, Ivanuš U, Primic Žakelj M. Redki raki. In: Kraigher A, Berger T, Nikolič S, eds. *Javno zdravje - povezovanje za zdravje: zbornik izvlečkov = Public health - networking for health*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2016: 115.


2017

- Bonaventure A, Harewood R, Stiller CA, Gatta G, Primic-Žakelj M, Žagar T et al. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol*; 2017; 4: e202-17.
- Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Primic-Žakelj M, et al. Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages. *Eur J Cancer*; 2017; 83: 43–55.
- Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Primic-Žakelj M et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. *The Lancet Oncology*. 2017 Aug;18(8):1022-39. PubMed PMID: 28687376.
- Georgakis MK, Karalexi MA, Kalogirou EI, Ryzhov A, Zborovskaya A, Žagar T et al. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. *J Neurooncol*; 2017; 131: 163-75.
- Georgakis MK, Panagopoulou P, Paphoma P, Tragiannidis A, Ryzhov A, Žagar T et al. Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US. *Eur J Cancer*; 2017; 86: 46–58.
- Georgakis MK, Paphoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Žagar T et al. Malignant central nervous system tumors among adolescents and young adults (15–39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. *Cancer*; 2017; 123: 4458-71.
- Horvat M, Potočnik U, Repnik K, Kavalarić R, Zadnik V, Potrč S et al. Single Nucleotide Polymorphisms in Genes MACC1, RAD18, MMP7 and SDF-1a As Prognostic Factors in Resectable Colorectal Cancer. *Radiol Oncol*; 2017; 51: 151-9.
- Huang L, Jansen L, Balavarca Y, Molina-Montes E, Primic-Žakelj M, Zadnik V et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. *Gut*; 2017: Epub ahead of print.
- Karalexi MA, Georgakis MK, Dessypris N, Ryzhov A, Zborovskaya A, Žagar T et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. *Hematol Oncol*. 2017; 35: 608-18.
- Matz M, Coleman MP, Carreira H, Salmeron D, Primic-Žakelj M, Žagar T et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). *Gynecol Oncol*. 2017; 144: 396–404.
- Matz M, Coleman MP, Sant M, Chirlaque MD, Primic-Žakelj M, Žagar T et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). *Gynecol Oncol*. 2017; 144: 405-13.

- Perharič L, Martinčič M, Uršič S, Kukec A, Zadnik V, Mazej D et al. Poglobljena ocena tveganja za zdravje otrok zaradi izpostavljenosti arzenu v občini Zagorje ob Savi. Ljubljana: Nacionalni inštitut za javno zdravje; 2017.
- Ponti A, Anttila A, Ronco G, Primic-Žakelj M, Ivanuš U, Jarm K et al. Against cancer: cancer screening in the European Union. Lyon: International Agency for Research on Cancer; 2017.
- Primic-Žakelj M. Program dela Zveze slovenskih društev za boj proti raku v letu 2017. Ljubljana: Zveza slovenskih društev in regijskih društev za boj proti raku; 2017: 34–38.
- Primic-Žakelj M, Ivanuš U, eds. Zbornik predavanj, 7. izobraževalni dan programa ZORA z mednarodno udeležbo, Brdo pri Kranju, 17. maj 2017. Ljubljana: Onkološki inštitut; 2017.
- Ranfl M, Zadnik V. Epidemiologija rakov glave in vratu v Sloveniji 1983–2012 = Epidemiology of head and neck cancer in Slovenia 1983–2012. Medicinski razgledi 2017; 56: 277-91.
- Rotovnik Kozjek N, Kompan L, Žagar T, Mrevlje Ž. Influence of enteral glutamine on inflammatory and hormonal response in patients with rectal cancer during preoperative radiochemotherapy. Eur J Clin Nutr. 2017; 71: 671-3.
- Skopec B, Škerget M, Žontar D, Zadnik V, Zver S. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr. 2017; 129: 545-51.
- Velenik V, Šečerov-Ermenc A, But-Hadžić J, Zadnik V. Health-related Quality of Life Assessed by the EORTC QLQ-C30 Questionnaire in the General Slovenian Population. Radiol Oncol.
- Zadnik V. Epidemiologija raka zunanjega spolovila. In: Merlo S, Šegedin B, eds. Rak zunanjega spolovila: zbornik znanstvenih prispevkov. Ljubljana: Združenje za radioterapijo in onkologijo SZD, Sekcija internistične onkologije SZD, Onkološki inštitut; 2017: 10-3.
- Zadnik V. Epidemiologija RDČD: breme raka debelega črevesa in danke. In: Sodobna obravnava raka debelega črevesa in danke: zbornik prezentacij: simpozij za strokovno javnost, 31. marec 2017, Maribor. Maribor: Medicinska fakulteta; 2017: 5–16.
- Zadnik V. Rak in druge zdravstvene posledice kajenja. In: Belović B, Primic-Žakelj M, Zdešar A, eds. Kajenje in zdravje - nikoli končana zgodba. Ljubljana: Zveza slovenskih društev za boj proti raku; 2017: 67–77.
- Zadnik V. Vzpostavitev kliničnega registra melanom Registra raka Republike Slovenije. In: Boc M, Reberšek M, eds. 13. šola malignega melanoma, 10. marec 2017, Ljubljana. Ljubljana: Onkološki inštitut; 2017: 11-2.
- Zadnik V, Primic-Žakelj M, Jarm K, Žagar T. Time trends and spatial patterns in the mesothelioma incidence in Slovenia, 1961–2014. Eur J Cancer Prev. 2017; 26: S191-S6.
- Zadnik V, Primic-Žakelj M, Lokar K, Jarm K, Ivanuš U, Žagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol. 2017; 51: 47–55.
- Zadnik V, Primic-Žakelj M, Žagar T. Cancer survival in children and adolescents in last 50 years in Slovenia. In: Grell 2017. Bruxelles: Belgian Cancer Registry; 2017: 47.
- Zadnik V, Primic-Žakelj M, Žagar T, Škrlec F, Lokar K, Čampa A. Pregled obravnave bolnikov s kožnim melanomom v Sloveniji za incidenčna leta 2011–2016. Ljubljana: Onkološki inštitut, Epidemiologija in register raka, 2017.
- Žagar T, Primic-Žakelj M, Zadnik V. Rare cancers in Slovenia. In: Ensuring quality and use of data from cancer registries in the 21st century. Utrecht: ENCR; 2017: 129.







POROČILO RR št. 57
REPORT No. 57
Ljubljana 2018
ISSN 1318-5845